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ABSTRACT 
In Canada, colorectal cancer is the second leading cause of death from cancer in men and 
the third leading cause of death from cancer in women.  Several factors contribute to the 
development of cancer.  Genetic predisposition, diet, and lifestyle habits are some of the 
major factors for colorectal cancer development.  In the diet related factors, 
epidemiological studies suggest that consumption of whole grains rich in dietary fiber are 
associated with low incidence of human colon cancer.  Recent studies have also shown 
that, in addition to dietary fiber, the type of dietary fiber and other compounds such as 
phenolic acids present in cereal grain bran may also have a role to play in colon cancer 
prevention.  In a recent study, eleven major phenolic acids which differed in anti-oxidant 
activity were identified in wheat bran from wheat varieties belonging to six different 
market classes.  The main objective of this study was to develop an in vitro cell culture 
based assay system to study the effect of phenolic acids on colon cancer development.  
Another objective was to study the effect of phenolic acids on selected molecular markers 
associated with cell proliferation, apoptosis and inflammation.  Two well established 
colon carcinoma cell lines HT-29 and HCT 116 were treated with varying concentrations 
of fourteen phenolic acids to study their effect on cell survival and proliferation.  In 
addition, immunohistochemical assays were performed on treated cells for two cell 
proliferation markers (Cyclin D1 and Ki67), an apoptosis marker (Bax) and three 
inflammatory markers (Beta-catenin, COX-2 and iNOS).  Treatment of phenolic acids 
inhibited the growth of both the cell lines, however the effects varied with phenolic acid 
and cell line used in the assay.  As determined by IC50, the growth of HCT 116 cells was 
inhibited the most by caffeic, ellagic, and gallic acids with IC50 of 0.22 mM, 0.17 mM, 
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and 0.15 mM, respectively.  On the other hand, caffeic, chlorogenic, and gallic acids are 
most effective in preventing the growth of HT-29 cells, with IC50 at 0.06 mM, 0.28 mM, 
and 0.30 mM, respectively.  Immunohistochemical and Western Blotting studies revealed 
that phenolic acids differentially affected markers for cell proliferation, apoptosis and cell 
inflammation.  In most of the cases, phenolic acid treatments up-regulated the pro-
apoptosis marker Bax, while it down-regulated cell proliferation marker Cyclin D1.  The 
results clearly show that a cell culture based assay can be used to study the effect of 
phenolic acids or other chemical constituents isolated from plants to study their effect on 
colon cancer cell lines.  Statistical analysis revealed that only in very limited cases, 
results of molecular markers correlated to cell growth and proliferation.  Therefore, to 
draw firm conclusions, more detailed and extensive studied need to be completed using 
different phenolic acids, the two cell lines and more replications.  However, this study has 
developed the necessary protocols and provided some indicative results such as most of 
the phenolic acids induced pro-apoptosis pathway in both the colon cancer lines.  Future 
studies with extracted phenolic acids from wheat bran using the cell culture system 
optimized in this study can be used to define the role of different wheat varieties in colon 
cancer prevention.   
 iv 
ACKNOWLEDGEMENTS 
 I would like to take this opportunity to thank the people who have supported me 
during my Master’s studies.  
 First of all, I would like to thank my supervisors, Drs. Rajni Chibbar and Ravi 
Chibbar.  It is hard to overstate my gratitude to both my supervisors.  Throughout my 
master’s program and thesis-writing period, they provided encouragement, sound advice, 
good accompany and lots of brilliant ideas.  They are the best professors I have ever met.  
This thesis will never be possible without them.    
 I greatly appreciate all the assistance provided by my advisory committee 
members: Drs. Rani Kanthan, Selliah Kanthan, John Krahn, Qing Meng, Mabood 
Qureshi and Joseph Blondeau. 
I would also like to thank Ms. Heather Neufeld and Dr. Sarita Jaiswal for their 
professional expertise, advice and help in many different ways.  
I would like to thank my boyfriend, Ze Long Lim for supporting and 
accompanying me.  He keeps me motivated through tough times.  
I am very grateful to my parents for supporting me both financially and 
emotionally.  Without them I would never have the opportunity to study in Canada and to 
have this amazing experience.  
This project was funded by the Canada Research Chairs (CRC), Natural Sciences 
and Engineering Research Council of Canada (NSERC), and Canada Foundation for 
Innovation (CFI) program. 
 
 
 
 v 
TABLE OF CONTENTS 
 
PERMISSION TO USE .................................................................................................. i 
ABSTRACT .................................................................................................................... ii 
ACKNOWLEDGMENTS............................................................................................... iv 
TABLE OF CONTENTS............................................................................................... . v 
LIST OF TABLES .......................................................................................................... x 
LIST OF FIGURES......................................................................................................... xi 
LIST OF ABBREVIATIONS......................................................................................... xiv 
 
1.0 INTRODUCTION..................................................................................................... 1 
 
2.0 LITERATURE REVIEW.......................................................................................... 5 
2.1 Functions of the Colon .............................................................................................. 5 
2.2 Understanding Colorectal Cancer ............................................................................. 6 
 2.2.1 Sporadic Colorectal Cancer ....................................................................... 6 
 2.2.2 Inherited Colorectal Cancer Disorder ........................................................ 7 
  2.2.2.1 Familial Adenomatous Polyposis (FAP) .................................... 8 
  2.2.2.2 Hereditary Non-polyposis Colorectal Cancer ............................. 13 
2.3 Pathogenesis of Colorectal Cancer ........................................................................... 15 
 2.3.1 Adenoma-Carcinoma Pathogenesis of Colorectal Cancer ......................... 15 
2.4 Mouse Models for Colorectal Cancer ....................................................................... 19 
 2.4.1 Mouse Models for Colorectal Cancer and FAP ......................................... 20 
 2.4.2 Mouse Models for HNPCC ........................................................................ 21 
2.5 Chemoprevention of Colorectal Cancer by Dietary Fiber – Phenolic Acids ............ 22 
 2.5.1 Dietary Fiber .............................................................................................. 22 
 2.5.2 The Role of Dietary Fiber in Colorectal Cancer ........................................ 23 
 2.5.3 Possible Dietary Fiber-Mediated Mechanisms in Carcinogenesis ............. 24 
 2.5.4 Phenolic Acids ........................................................................................... 27 
 2.5.5 Wheat – A Major Source of Energy in Human Nutrition .......................... 29 
 2.5.6 Role of Phenolic Acids in Chemoprevention ............................................. 29 
 vi 
2.6 Cyclooxygenase-2 (COX-2) ..................................................................................... 31 
 2.6.1 Cyclooxygenases (COXs) .......................................................................... 31 
 2.6.2 Role of PGs in Colon Carcinogensis ......................................................... 32 
 2.6.3 Role of COX-2 in Colon Carcinogensis .................................................... 34 
2.7. Programmed Cell Death or Apoptosis ..................................................................... 38 
 2.7.1 Apoptosis-related Proteins: B-cell lymphoma 2 (Bcl-2) Family  
          Members .................................................................................................... 39 
 2.7.2 Apoptosis Mechanisms in the Unstreesed and Stressed Induced  
          Intestine ...................................................................................................... 42 
2.7.3 Regulation of Apoptosis by APC ........................................................................... 44 
2.8 Mitotic Cell Cycle ..................................................................................................... 44 
 2.8.1 Role of Cyclin D1 in Cell cycle and Colorectal Cancer ............................ 45 
2.9 Role of Inducible Nitric Oxide Synthase (iNOS) in Colorectal Cancer ................... 48 
 2.9.1 Nitric Oxide Synthase (NOS) .................................................................... 48 
 2.9.2 iNOS and Colorectal Cancer ...................................................................... 49 
 
3.0 HYPOTHESIS .......................................................................................................... 52 
 
4.0 THESIS OBJECTIVES ............................................................................................ 53 
 
5.0 MATERIALS AND METHODS .............................................................................. 54 
5.1 Chemicals and Reagents ........................................................................................... 54 
5.2 Phenolic Acids Used in This Study .......................................................................... 54 
5.3 Human Colon Cancer Cell Culture and Growing Conditions .................................. 54 
5.4 Cell Culture Based Screening Assay ........................................................................ 58 
 5.4.1 Cell Treatment with Phenolic Acid Compounds ....................................... 58 
 5.4.2 Cell Harvesting and Agar-Cell-Pellet Blocks ............................................ 58 
5.5 Cell Viability ............................................................................................................. 59 
 3.5.1 Trypan Blue Exclusion Method ................................................................. 59 
5.6 Immunohistochemistry Analysis .............................................................................. 60 
 5.6.1 Immunohistochemical Staining ................................................................. 60  
 vii 
 5.6.2 Evaluation of Immunostaining ................................................................... 61 
5.7 Western Blot Analysis .............................................................................................. 62 
 5.7.1 Sample Preparation and Protein Extraction ............................................... 62 
 5.7.2 BCA Protein Quantitation .......................................................................... 62 
5.8 SDS-PAGE and Western Blotting ............................................................................ 62 
5.9 Immunodetection ...................................................................................................... 63 
 
6.0 RESULTS  ................................................................................................................. 64 
6.1 Sensitivity of Individual Phenolic Acids on Cell Proliferation ................................ 64 
6.2 HT-29 Cell Viability ................................................................................................. 64 
6.3 HCT 116 Cell Viability ............................................................................................. 66 
6.4 Immunohistochemical Analysis ................................................................................ 68 
6.5 Modulation of Marker Proteins by Cinnamic Acid Derivative Phenolic  
       Acids on HT-29 Cell Line ........................................................................................ 70 
 6.5.1 Caffeic Acid ............................................................................................... 70 
 6.5.2 Chlorogenic Acid ....................................................................................... 70 
 6.5.3 p-Coumaric Acid ........................................................................................ 72 
 6.5.4 Ferulic Acid ............................................................................................... 72 
 6.5.5 Sinapic Acid ............................................................................................... 74 
 6.5.6 3, 4-Dimethoxycinnamic Acid ................................................................... 74  
6.6 Modulation of Marker Proteins by Benzoic Acid Derivative Phenolic  
       Acids on HT-29 Cell Line ........................................................................................ 76 
 6.6.1 Ellagic Acid ............................................................................................... 76 
 6.6.2 Gallic Acid ................................................................................................. 76 
 6.6.3 Protocatechuic Acid ................................................................................... 76 
 6.6.4 Salicylic Acid ............................................................................................. 78 
 6.6.5 Syringic Acid ............................................................................................. 79 
 6.6.6 Vanillic Acid .............................................................................................. 79 
 6.6.7 2, 5-Dihydroxybenzoic Acid ...................................................................... 81 
 6.6.8 4-Hydroxybenzoic ...................................................................................... 82 
 
 viii 
6.7 Modulation of Maker Proteins by Cinnamic Acid Derivative Phenolic  
       Acids on HCT 116 Cell Line ................................................................................... 83 
 6.7.1 Caffeic Acid ............................................................................................... 83 
 6.7.2 Chlorogenic Acid ....................................................................................... 84 
 6.7.3 p-Coumaric Acid ........................................................................................ 84 
 6.7.4 Ferulic Acid ............................................................................................... 84 
 6.7.5 Sinapic Acid ............................................................................................... 86 
 6.7.6 3, 4-Dimethoxycinnamic Acid ................................................................... 86 
6.8 Modulation of Marker Proteins by Benzoic Acid Derivative Phenolic  
       Acids on HCT 116 Cell Line ................................................................................... 89 
 6.8.1 Ellagic Acid ............................................................................................... 89 
 6.8.2 Gallic Acid ................................................................................................. 90 
 6.8.3 Protocatechuic Acid ................................................................................... 90 
 6.8.4 Salicylic Acid ............................................................................................. 90 
 6.8.5 Syringic Acid ............................................................................................. 93 
 6.8.6 Vanillic Acid .............................................................................................. 93 
 6.8.7 2, 5-Dihydroxybenzoic Acid ...................................................................... 93 
 6.8.8 4-Hydroxybenzoic ...................................................................................... 94 
6.9 Western Blot Analysis .............................................................................................. 97 
 
7.0 DISCUSSION ........................................................................................................... 104 
7.1 Human Colon Cells in Different Neoplastic Stages Were Used for the Study ......... 104 
7.2 Differential Growth Inhibitory Effects of Individual Phenolic Acids on  
       HT-29 and HCT 116 Cell Lines ............................................................................... 104 
7.3 Differential Effect of Phenolic Acids on Markers for Colon Cancer ....................... 108 
7.4 Ellagic Acid Affects Cell Proliferation, Apoptosis and Inflammatory Markers ...... 110 
7.5 Effect of Gallic Acid on HT-29 and HCT 116 Cells ................................................ 112 
7.6 Effect of Caffeic Acid on HT-29 and HCT 116 Cells .............................................. 113 
7.7 Effect of Chlorogenic Acid on HT-29 Cells ............................................................. 114 
7.8 Anti-oxidant Capacities of Phenolic Acids ............................................................... 115 
7.9 General Conclusions ................................................................................................. 115 
 ix 
7.10 Future Directions .................................................................................................... 117 
 
8.0 REFERENCES ......................................................................................................... 118 
 
9.0 APPENDIX ............................................................................................................... 144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
LIST OF TABLES 
Table              Page 
Table 1.1  The identified mismatch repair genes which cooperated as  
 site of mutation in HNPCC ..................................................................... 15 
Table 7.1 Distinguishing characteristics of human colon cancer cell lines  
 HT-29 and HCT 116 used in this study .................................................. 105 
Table 7.2 Correlation coefficients to see the effects on both the cell lines 
 together ................................................................................................... 109 
Table 7.3 Anti-oxidant activity of 50 µg ml
-1
 phenolic acid standards................... 116 
 
 
 
 xi 
LIST OF FIGURES 
Figure             Page 
Figure 2.1  Functional domains of APC protein ....................................................... 9 
Figure 2.2  The Wnt signalling pathway ................................................................... 12 
Figure 2.3 Colorectal cancer occurs in a multi-step process, in which four  
  genes are mutated in a specific order ...................................................... 16 
Figure 2.4 Role of COX in prostaglandin synthesis ................................................. 33 
Figure 2.5 The β-catenin pathway provides a link between COX-2 and  
 colorectal cancer ..................................................................................... 35 
Figure 2.6 The cell cycle clock machinery ............................................................... 46 
Figure 5.1 Chemical structures of benzoic acid derivative phenolic acids  
 used in this study ..................................................................................... 56 
Figure 5.2 Chemical structures of cinnamic acid derivative phenolic acids  
 used in this study ..................................................................................... 57 
Figure 6.1  Effect of cinnamic acid derivative phenolic acids on HT-29  
 colon cancer cell growth ......................................................................... 65 
Figure 6.2  Effect of benzoic acid derivative phenolic acids on HT-29  
 colon cancer cell growth ......................................................................... 65 
Figure 6.3 Effect of cinnamic acid derivative phenolic acids on  
 HCT 116 colon cancer cell growth ......................................................... 67 
Figure 6.4 Effect of benzoic acid derivative phenolic acids on  
 HCT 116 colon cancer cell growth ......................................................... 67 
Figure 6.5 The growth inhibitory effect of phenolic acids on HCT 116  
 and HT-29 cells ....................................................................................... 69 
Figure 6.6 Effect of caffeic acid on HT-29 cell line ................................................ 71 
Figure 6.7 Effect of chlorogenic acid on HT-29 cell line ........................................ 71 
Figure 6.8 Effect of p-coumaric acid on HT-29 cell line ......................................... 73 
Figure 6.9 Effect of ferulic acid on HT-29 cell line ................................................. 73 
Figure 6.10  Effect of sinapic acid on HT-29 cell line ................................................ 75 
Figure 6.11  Effect of 3, 4-dimethoxycinnamic acid on HT-29 cell line .................... 75 
 xii 
Figure 6.12  Effect of ellagic acid on HT-29 cell line ................................................. 77 
Figure 6.13 Effect of gallic acid on HT-29 cell line .................................................. 77 
Figure 6.14  Effect of protocatechuic acid on HT-29 cell line .................................... 78 
Figure 6.15  Effect of salicylic acid on HT-29 cell line .............................................. 80 
Figure 6.16 Effect of syringic acid on HT-29 cell line .............................................. 80 
Figure 6.17  Effect of vanillic acid on HT-29 cell line ............................................... 81 
Figure 6.18 Effect of 2, 5-dihydroxybenzoic acid on HT-29 cell line ....................... 82 
Figure 6.19  Effect of 4-hydroxybenzoic acid on HT-29 cell line .............................. 83 
Figure 6.20 Effect of caffeic acid on HCT 116 cell line ............................................ 85 
Figure 6.21  Effect of chlorogenic acid on HCT 116 cell line .................................... 85 
Figure 6.22  Effect of p-coumaric acid on HCT 116 cell line ..................................... 87 
Figure 6.23  Effect of ferulic acid on HCT 116 cell line ............................................. 87 
Figure 6.24  Effect of sinapic acid on HCT 116 cell line ............................................ 88 
Figure 6.25  Effect of 3, 4-dimethoxycinnamic acid on HCT 116 cell line ................ 88 
Figure 6.26 Effect of ellagic acid on HCT 116 cell line ............................................ 91 
Figure 6.27  Effect of gallic acid on HCT 116 cell line .............................................. 91 
Figure 6.28 Effect of protocatechuic acid on HCT 116 cell line ............................... 92 
Figure 6.29  Effect of salicylic acid on HCT 116 cell line .......................................... 92 
Figure 6.30 Effect of syringic acid on HCT 116 cell line .......................................... 95 
Figure 6.31  Effect of vanillic acid on HCT 116 cell line ........................................... 95 
Figure 6.32  Effect of 2, 5-dihydroxybenzoic acid on HCT 116 cell line ................... 96 
Figure 6.33  Effect of 4-hydroxybenzoic acid on HCT 116 cell line .......................... 96 
Figure 6.34 Western blotting analysis to detect pro-apoptotic Bax in  
 phenolic acid treated and untreated HCT 116 cells ................................ 98 
Figure 6.35 Western blotting analysis to detect Cyclin D1 in phenolic acid  
 treated and untreated HCT 116 cells ....................................................... 99 
Figure 6.36 Western blotting analysis to detect pro-apoptotic Bax in  
 phenolic acid treated and untreated HT-29 cells ..................................... 100 
Figure 6.37 Western blotting analysis to detect Cyclin D1 in phenolic acid 
  treated and untreated HT-29 cells ........................................................... 101 
 
 xiii 
Figure 6.38 Relative quantitation of Western Blot of cell treatments from  
 human colon cancer cell line HCT 116 probed with primary  
 antibody against Bax or Cyclin D1 ......................................................... 102 
Figure 6.39 Relative quantitation of Western Blot of cell treatments from  
 human colon cancer cell line HT-29 probed with primary  
 antibody against Bax or Cyclin D1 ......................................................... 103 
Figure 7.1 The half maximal inhibitory concentration (IC50) of individual 
  phenolic acids on HT-29 colon cancer cell line ...................................... 106 
Figure 7.2 The half maximal inhibitory concentration (IC50) of individual  
 phenolic acids on HCT 116 colon cancer cell line ................................. 107 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 xiv 
LIST OF ABBREVIATIONS 
ABTS    2, 2’-Azinobis(3-ethylbenzthiazoline-6-sulfonic acid) 
AG   Aminoguanidine  
Apaf-1   Apoptosis protease-activating factor-1 
APC   Adenomatous polyposis coli 
ATP   Adenosine triphosphate 
AOM   Azoxymethane 
Bak   Bcl-2 homologous antagonist killer 
Bax   Bcl-2-associated X 
Bcl-2   B-cell lymphoma 2 
Bcl-xL   B-cell lymphoma-extra large 
Caspase   Cysteinyl aspartate-specific protease 
CDK   Cyclin dependent kinase  
CHRPE  Congenital hypertrophy of the retinal pigment epithelium 
CIN   Chromosomal instability 
CK1   Casein kinase 1  
cNOS    Constitutive nitric oxide synthase  
COX-2  Cyclooxygenase-2 
DCC   Deleted in colon cancer 
DMEM  Dulbecco's modified Eagle's medium 
DMH   Dimethylhydrazine 
DMSO   Dimethyl sulfoxide  
DNA   Deoxyribonucleic acid 
D-PBS   Dulbecco’s phosphate-buffered saline  
DPPH   2, 2-Diphenyl-1-picrylhydrazyl 
DSH   Dishevelled 
ecNOS   Endothelial constitutive nitric oxide synthase  
EDTA   Ethylenediaminetetraacetic acid 
EP2   E-prostanoid-2  
FAP   Familial adenomatous polyposis 
GLP-2   Growth hormone including peptide-2 
 xv 
GSK-3β   Glycogen synthase kinase-3β 
H2O2   Hydrogen peroxide  
HNPCC  Hereditary nonpolyposis colorectal cancer 
IC50   Half maximal inhibitory concentration 
IGF   Insulin-like growth factor 
iNOS   Inducible nitric oxide synthase 
L-NAME   1-N(G)-nitroarginine methyl ester  
MA   Mitochondrial anchorage 
MGMT  O
6
-methylguanine-DNA methyltransferase 
Min   Multiple intestinal neoplasia 
MLH1   MutL homologue 1 
mM   Millimolar  
MNU    Methylnitrosourea  
MSH2   MutS homologue 2 
MSI   Microsatellite instability 
ncNOS   Neuronal constitutive nitric oxide synthase 
NES   Nuclear export signal 
NO   Nitric oxide 
NO2   Nitrite  
NO3   Nitrate 
NSAIDs   Non-steroidal anti-inflammatory drugs  
PBIT    S,S′-1,4-phenylene-bis(1,2-ethanediyl)bis-isothiourea  
PBS   Phosphate-buffered saline  
PG   Prostaglandin 
PhIP    2-Amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine  
PI3K    Phosphatidylinositol-3′-kinase  
PMS   Post Meiotic Segregation 
PP2A   Protein phosphatise 2A 
PGG2   Prostaglandin G2  
PGH2   Prostaglandin H2 
PVDF    Polyvinylidene difluoride 
 xvi 
RB   Retinoblastoma protein  
SC-51   L-N(6)-1-iminoethyl)lysine tetrazolamide 
SDS   Sodium dodecyl sulfate 
SDS-PAGE   Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
Tcf/lef   T cell factor/lymphoid enhancer factor 
TEAC   Trolox equivalent anti-oxidant capacity 
TPA    12-O-tetradecanoylphorbol-13-acetate  
Trypsin-EDTA  Trypsin-ethylenediaminetetraacetic acid  
UV   Ultraviolet  
 
 
 
 
 
 
 
 
 
 
 1 
1.0 INTRODUCTION 
Alimentary tract diseases are major causes of morbidity and mortality all around 
the world.  The digestive tract is particularly vulnerable to cancers, the incidence of 
which shows significant geographical variation (Johnson, 2007).  World-wide, colorectal 
cancer is the fourth most common cancer in men and third most common cancer in 
women (Parkin et al., 2005).  Significant international variations in the incidence of 
colorectal cancer have been observed (Parkin, 2004; Center et al., 2009b).  Colorectal 
cancer is one of the three most common causes of death in industrialised western 
countries, but it is significantly lower in less developed world.  A diet low in fiber, 
obesity, physical inactivity, and smoking have been associated with high incidence of 
colorectal cancer in the developed world (Giovannucci, 2002; Giovannucci and Wu, 
2006; Botteri et al., 2008).  However, the incidence of colorectal cancer is on the rise in 
newly-developed countries (Center et al., 2009b), where at one time the risk was 
considerably lower (Parkin et al., 2005).  The high rates of cancers observed in countries 
previously with low colorectal cancer incidences is attributed to Westernization of diet, 
increase in obesity, and inactivity (Center et al., 2009a).  In Canada, colorectal cancer is 
the second leading cause of death from cancer in men and the third leading cause of death 
from cancer in women (Loraine et al., 2009).   
Several factors contribute to the development of colorectal cancer.  There is 
growing evidence that genetic predisposition, diet, and lifestyle habits are some of the 
major contributing factors for colorectal cancer development.  Within populations at high 
risk of colon cancer development, the lifetime risk of developing the disease is 
approximately 5 - 6% (Johnson, 2007).  Genetic syndromes such as familial adenomatous 
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polyposis (FAP), Peutz Jeghers syndrome, juvenile polyposis, and hereditary 
nonpolyposis colorectal cancer account for approximately 3% of all cases (Aaltonen et 
al., 1998; Salovaara et al., 2000; Percesepe et al., 2001; Samowitz et al., 2001) and are 
not responsible for the two-fold increased risk in first-degree relatives of sporadic 
colorectal cancer patients (de Jong et al., 2002).  These observations suggest that low-
penetrance genes are involved in the disease process, and the development of colorectal 
cancer is a combination of environmental and genetic factors (de Jong et al., 2002; 
Heavey et al., 2004).   
Diet is one of the major environmental factors affecting cancer development.  
Among all the diet-determined cancers, colorectal cancer is one of the most strongly 
related to one or more components in diet (Wirfält et al., 2009).  Consumption of diets 
rich in fiber, folate, and calcium have been associated with reduced risk of colorectal 
cancer (Giovannuci et al., 2002; Bingham et al., 2003; Norat and Riboli, 2003; Larsson et 
al., 2006), while diets rich in meat and fat increase the risk of colorectal cancer 
(Giovannuci et al., 1992; Norat et al., 2005).  It has been suggested that inhibitory effects 
of dietary fiber on the development of colon cancer depend on the source of fiber 
(Maziya-Dixon et al., 1994; Kritchevsky et al., 1999).  Mice fed with wheat bran fiber 
led to 40% lower incidence of dimethylhydrazine (DHM)-induced colon cancer as 
compared with mice fed with cellulose-containing diets (Kritchevsky et al., 1999), 
suggesting a role for other compounds besides fiber in prevention of colon cancer.  A 
subsequent study reported that the orthophenolic content of wheat grain has the ability to 
prevent colon cancer cell growth in Caco-2 cell lines (Drankhan et al., 2003).  
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Collectively, these data suggest that wheat bran components confer a protective role in 
prevention of colon cancer cell growth. 
Wheat (Triticum aestivum L.) is one of the three important cereal grains with a 
global production of about 600 million tonnes annually (Shewry, 2009).  Wheat grain, a 
rich source of carbohydrates and protein, accounts for nearly 30% of grain consumption.   
Due to its unique properties, it is a major source of calories in human and animal diets.  
Wheat grains contain significant amounts of phenolic acids, mostly localized in the bran 
(Verma et al., 2008; Verma et al., 2009).   
Plant phenolic acids are defined as bioactive non-nutrient compounds in fruits, 
vegetables, grains, and other plant-based foods (Liu et al., 2004).  Phenolic acids play a 
major role in providing essential functions in the reproduction and growth of the plants 
and provide structural integrity to the cell wall (Klepacka and Fornal, 2006).  
Structurally, phenolic acid can be subdivided into benzoic acid and cinnamic acid 
derivatives (Kim et al., 2006).  For example, vanillic and salicylic acids are benzoic acid 
derivatives whereas ferulic and caffeic acids are cinnamic acid derivatives (Abdel-Aal et 
al., 2001).  A preliminary animal study demonstrated that mice that fed on all wheat-
based diets gained 30% less weight as compared to mice on a regular diet and, in 
addition, mice fed with a diet made with CDC Teal wheat had lower number of 
azoxymethane (AOM)-induced aberrant crypt foci as compared to mice fed with rat chow 
diet (Chibbar et al., unpublished).   
More recently a detailed study of wheat bran from six cultivars representing six 
market classes of wheat, identified eleven phenolic acids and a lignan which differed in 
their anti-oxidant capacities (Verma et al., 2009).  Gallic acid showed the strongest anti-
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oxidant activity followed by ellagic, caffeic, and chlorogenic acids (Verma et al., 2009).  
Phenolic acids can also confer their protective role in health by chelating metal ions 
(Liyana-Pathirana and Shahidi, 2006), detoxifying enzymes (Yoshioka et al., 1995), and 
inhibiting transcription factors that initiate and promote tumor growth (Yoshioka et al., 
1995).  However, the precise mechanism of cereal grains in colorectal prevention is not 
well understood.  
To understand the mechanism of wheat bran in colorectal cancer prevention, we 
examined the effects of individual phenolic acids present in wheat bran on the growth of 
two human colon cancer cell lines (HT-29 and HCT 116).  In addition, we studied the 
effects of individual phenolic acids on the expression of selected genetic markers in 
treated cells by immunohistochemical studies.  
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2.0 LITERATURE REVIEWS 
2.1 Functions of the Colon 
 Under normal circumstances, the colonic epithelium is constantly renewed by 
crypt proliferative cells which migrate upward along the crypt-villi axis as they 
terminally differentiate (Lipkin, 1973).  The average time for these cells to proliferate is 
one day, and approximately 25% of the colonic epithelium is rejuvenated everyday.  
Moreover, the crypt epithelial cells of the entire colon and rectum are replaced every 
three to four days (Lipkin, 1985).  The cell renewal rate in the colon and rectum may be 
regulated neurally or hormonally.  Mitotic rate in the rat colonic crypts is low following 
chemical sympathectomy and is increased by the treatment with Metaraminol, a drug that 
releases the norepinephrine from nerve terminals (Tutton and Barkla, 1980).  Hormones 
and paracrines secreted by intestinal enteroendocrine cells and pancreatic cells promote 
epithelial and stem cell turnover (Medh and Thompson, 2000). Over expression of 
growth hormone including peptide-2 (GLP-2) and insulin-like growth factor (IGF) 
stimulate intestinal cell proliferation in mice (Ulshen et al., 1993; Tsai et al., 1997), of 
which GLP-2 prevents enterocytes apoptosis (Tsai et al., 1997).  
 The other factors which are significant in maintaining normal colonic mucosa are 
B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X (Bax).  The colonic epithelial cells 
express the pro-apoptotic Bax protein while the colonic stem cells are rich in anti-
apoptotic Bcl-2 protein (Krajewski et al., 1994; Jones and Gores, 1997).  Therefore the 
proliferation rate is higher in the base of crypts, whereas apoptosis occurs mainly at 
luminal surface of human colonic epithelium.  This role of Bcl-2 is further supported by 
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the finding that incidence of spontaneous and induced apoptosis is increased in the base 
of colonic crypts in Bcl-2 knock out C57BL/6 mice (Merritt et al., 1995).  
2.2 Understanding Colorectal Cancer  
 Colorectal cancer is one of the most common malignancies in developed nations. 
It is the second leading cause of cancer deaths in Canada.  In 2009, approximately 22,000 
Canadians were diagnosed with colorectal cancer and there were 9,100 deaths. Incidence 
of colorectal cancer is higher in developed countries such as North America, Australia, 
and New Zealand, in which the population is more economically privileged and 
consumes a diet rich in animal-based food products (Rupnarain et al., 2004).  
Most of the colorectal cancers are in either sporadic or familial form, based on 
two distinct genomic instability pathways: chromosomal instability (CIN) and 
microsatellite instability (MSI) (Yamamoto et al., 2002; Grady, 2004; Imai and 
Yamamoto, 2008).  Tumors with CIN phenotype are characterized as aneuploid cancer 
with the suppressor pathway such as deregulation of deoxyribonucleic acid (DNA) 
replication check points and mitotic-spindle check points, whereas tumors with MSI 
phenotype are associated with the mutator pathway for diploid cancer (Grady, 2004; Imai 
and Yamamoto, 2008). 
2.2.1 Sporadic Colorectal Cancer 
 Nearly 85% of sporadic colorectal cancer is found to have CIN phenotype and is 
characterized with aneuploid cells, multiple chromosomal rearrangements, and 
accumulation of somatic mutations in oncogenes such as K-ras as well as tumor 
suppressor genes (Imai and Yamamoto, 2008).  Spontaneous somatic mutations in tumor 
suppressor adenomatous polyposis coli (APC) gene is an early event in colorectal 
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tumorigenesis and accounts for nearly 80% of sporadic colorectal cancer and in about 
50% of sporadic adenomas (Miyoshi et al., 1992; Powell et al., 1992; Imai and 
Yamamoto, 2008).  Thus, combining these data, spontaneous somatic mutation in 
colonocytes results in loss of wild type APC allele, thought to be associated with 
development of sporadic adenomatous polyps (Miyoshi et al., 1992). 
 Over 60% of all somatic mutations in APC occur within less than 10% of the 
coding sequence of the gene in a mutation cluster region in exon 15, between codons 
1286 and 1513 (Miyoshi et al., 1992).  Within this cluster, there are two hotspots for 
somatic mutations at codons 1309 and 1450 (Beroud and Soussi, 1996).  APC mutations 
within the cluster region are usually nonsense mutations and result in a truncated APC 
protein that lacks all of the axin binding sites and one or two of its 20-amino acid β-
catenin biding sites.  Moreover, one of two promoter regions of APC, promoter 1A but 
not promoter 2A, has been shown to be hypermethylated in approximately 30% of 
colorectal cancer but not in adenomas (Hiltunen et al., 1997).  Hypermethylation of 
promoter region 1A may impact second mutation and inactivation of APC leading to 
invasive colorectal cancer.  Mutations within APC gene in sporadic colon cancer are 
identical to mutations of APC in familial adenomatous polyposis patients.  
MSI due to mutation in mismatch repair genes occurs in approximately 15% of 
sporadic colorectal cancer (Imai and Yamamoto, 2008).   
2.2.2 Inherited Colorectal Cancer Disorder  
 Epidemiological studies have suggested that at least 10 - 15% of colorectal cancer 
is dominantly inherited (Houlston et al., 1992).  Two common types of inherited colonic 
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cancer include: the familial adenomatous polyposis (FAP) and the hereditary 
nonpolyposis colorectal cancer (HNPCC) (Lynch et al., 1966).  
2.2.2.1 Familial Adenomatous Polyposis (FAP) 
 FAP is an autosomal dominant inherited disease accounting for about 1 to 3% of 
all colorectal cancer cases (Grady, 2003).  FAP is characterized by development of 
hundreds to thousands of colorectal polyps in affected individuals.  These multiple 
colonic adenomas usually develop during the preteen age in FAP patients, and 
continuously proliferate throughout the colon.  Although large numbers of these benign 
tumors are not singly life-threatening, some of these benign tumors progress to become 
invasive lesions over a period of time.  If left untreated, the risk for a FAP patient to 
progress a carcinoma is almost certain by 40 to 50 years of age.  
FAP is caused by a germline mutation of an APC gene on chromosome 5q21 
(Kinzler et al., 1991).  APC is a tumor suppressor gene for colorectal cancer and 
produces a 312 kD protein consisting of 2834 amino acids (Polakis, 1997).  APC is a 
multifunctional protein that contains of an oligomerization domain and an armadillo 
region in the N-terminus, a number of 15-amino acids and 20-amino acids repeats in its 
central portion, as well as a C-terminus that consists of a basic domain and binding sites 
for EB1 and the human disc large protein (Polakis, 1997; Fearnhead et al., 2001) (Figure 
2.1).   
The multiple domains of the APC protein allow it to interact with a wide range of 
cytoplasmic proteins such as glycogen synthase kinase-3β (GSK-3β), axin proteins, and 
β-catenin (Fearnhead et al., 2001; Senda et al., 2005).  The oligomerization domain at the 
N-terminus of the APC protein allows APC to form homo-dimers with both wild type and 
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truncated mutant APC proteins (Polakis, 1997).  The armadillo region of APC binds to 
the regulatory B56 subunit of protein phosphatase 2A (PP2A) (Seeling et al., 1999), an 
enzyme that binds to axin through its catalytic subunit (Hsu et al., 1999).  PP2A may act 
as an antagonist to the GSK-3β phosphorylation of β-catenin (Seeling et al., 1999).  The 
15-amino acids and 20-amino acids repeat motifs provide binding sites for β-catenin after 
phosphorylation of each site by GSK-3β (Su et al., 1993; Munemitsu et al., 1995).  The 
cytoplasmic APC protein has two nuclear localization signals (NLS), explaining the 
presence of APC both in nucleus and cytoplasm (Zhang et al., 2000a) (Figure 2.1).  In 
addition, APC also has a nuclear export signal (NES), which is important for APC 
shuttling of β-catenin between nucleus and cytoplasm (Zhang et al., 2000a). 
 
Figure 2.1.  Functional domains of APC protein.  APC is a large protein of 2843 amino 
acids, comprising several protein-interaction domains as summarized.  Black arrows 
show active nuclear export signals (NESs).  Red arrows indicate sites for nuclear 
localization signals (NLSs).  (Adapted from Fearnhead et al., 2001)  
Multiple Cluster Region 
Codon 
Number 
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A tumor suppressor gene loses its tumor-suppressing function when both alleles at 
homologous chromosomes are completely impaired.  APC can produce normal gene 
product to suppress cellular proliferation as long as one of the allele is intact.   
Epidemiological studies on retinoblastoma show that mutation in the first allele is 
followed by inactivation of the second allele either through somatic APC mutation or loss 
of heterozygosity at this locus (Knudson, 2001).  All individuals born with one mutant 
allele developed hundreds to thousands of adenomatous polyps in colon during their 
twenties and loss of both copies of APC gene causes the development of cancer (Behrens 
et al., 2005; Jaiswal et al., 2005).  
More than 300 different mutations in APC gene have been reported to cause FAP 
(Laurent-Puig et al., 1998).  Patients with FAP show an interesting genotype and 
phenotype correlation with respect to the position of inherited APC mutation.  Germline 
mutations in APC are spread between codons 200 and 1600, with peaks at codons 1061 
and 1309, and rarely go beyond codon 1600 (Beroud and Soussi, 1996).  Most of the 
mutations, about 95%, are nonsense or frame shift mutations producing truncated APC 
protein (Beroud and Soussi, 1996; Laurent-Puig et al., 1998).  As much as 60% of 
patients develop duodenal tumors in which these tumors are usually located at the 
ampulla or the periampulla region (Kashiwagi and Spigelman, 2000).  
APC protein is an integral part of Wnt signal transduction pathway (Bienz and 
Clevers, 2000; Fearnhead et al., 2001), and plays an important role in cell-cell adhesion 
and apoptosis (Morin et al., 1996; Fearnhead et al., 2001).  When Wnt binds to its 
receptor frizzled, GSK-3β is inhibited and results in β-catenin stabilization and 
accumulation in cytoplasm.  The excess β-catenin translocates into the nucleus and binds 
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to the transcriptional activator t cell factor/lymphoid enhancer factor (tcf/lef), leading to 
transcription of target genes.  When APC is present in a cell, it binds to β-catenin, axin, 
and GSK-3β to form a large protein complex, to facilitate phosphorylation of β-catenin 
by casein kinase 1 (CK1) and then GSK-3β, resulting in proteosome-dependent 
degradation of phosphorylated β-catenin (Moon et al., 2004; Senda et al., 2005) (Figure 
2.2a).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 The loss of functional APC protein or β-catenin prevents GSK-3β-mediated 
phosphorylation and subsequent β-catenin degradation, resulting in β-catenin 
accumulation (Munemitsu et al., 1995), which, in turns, translocates into nucleus and 
switch  on transcription factors tcf/lef (Behrens et al., 2005) (Figure 2.2b).  Targets for 
transcriptional activation by β-catenin include the oncogene c-myc (He et al., 1998) and 
Cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 1999), which regulate cell 
cycle progression.  The role of β-catenin in regulating c-myc and Cyclin D1 strongly 
suggests that loss of APC function deregulates genes and leads to increased cell 
proliferation in mucosa.  
It has also been shown that APC participates in apoptosis regulation (Morin et al., 
1996).  Incorporation of a full length APC into HT-29 cells resulted in cell growth 
inhibition via increased apoptosis.  In another study, APC was shown to regulate 
cyclooxygenase-2 (COX-2) (Araki et al., 2003).  A wild type APC induced into HT-29 
cells down regulated COX-2 expression. COX-2 promoter did specifically bind to Tcf-4 
in an electrophoretic mobility shift assay (EMSA).  Thus, COX-2 is one of the 
downstream target of the APC/Wnt signalling, in which COX-2 expression is down-
regulated by APC and up-regulated by nuclear β-catenin.  
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Figure 2.2.  The Wnt signalling pathway.  (a) In the absence of active Wnt, APC 
associates with β-catenin and axin, phosphorylates β-catenin by CK1 and then GSK-3β.  
The phosphorylated β-catenin undergoes proteasome-dependent degradation resulting in 
inhibition of Wnt signalling pathway.  (b) The binding of Wnt to Frizzled receptor 
activates phosphoprotein Dishevelled (DSH) and inactivates GSK-3β, reducing 
phosphorylation and degradation of β-catenin.  As β-catenin accumulates, it transports 
into the nucleus and binds to tcf/lef transcriptional activators, leading to the expression of 
target genes.  (Adapted from Moon et al., 2004). 
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2.2.2.2 Hereditary Non-polyposis Colorectal Cancer 
 HNPCC is an autosomal dominant inherited disease which accounts for 3 to 5% 
of all colorectal cancer (Mecklin, 1987; Aaltonen et al., 1998).  Individuals with HNPCC 
develop carcinomas at an average age of 44 years if left untreated (Lynch et al., 1993).  
Precursor adenomas show a villous histology feature.  
Defective DNA repair caused by inactivation of DNA mismatch repair genes is 
both fundamental and initiating event in HNPCC.  Most cases of HNPCC are linked to 
mutations in genes of bacterial mutS and mutL gene family which encode homologues of 
bacterial post replicative DNA mismatch repair proteins MutS and MutL (Kolodner, 
1996).  The most commonly found mutations in HNPCC are in human MSH2 (mutS 
homologue 2) and MLH1 (mutL homologue 1) (Umar et al., 1996).  
As in APC-β-catenin scheme, there is accumulation of mutations in HNPCC but 
different genes are involved.  There are dozens of mismatch repair proteins in human cell 
system which coordinate in recognizing and repairing the repetitive misalignment during 
DNA replication and thus maintain fidelity of DNA replication.  The identified mismatch 
repair genes are listed in Table 1 (data modified from Lynch and de la Chapelle, 2003). 
DNA mismatch repair is initiated by two different complexes: a complex between 
MSH2-MSH6 for the recognition of single base mismatches and a complex between 
MSH2-MSH3 for the recognition of two to four base pair insertions or deletions 
(Kolodner, 1996; Umar et al., 1996).  Subsequently, a complex between MLH1 and 
another mutL homologues, PMS1 or PMS2 (Post Meiotic Segregation) interacts with 
MSH2 that binds to a base mispair.  The 3’-5’ exonuclease (EXO1) or PNCA are 
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believed to interact with MSH2/MLH1 in excision, resynthesis, or ligation (Umar et al., 
1996).  
Mutations in mismatch repair genes cause alteration of microsatellites, leading to 
MSI. MSI, a condition of instability in microsatellite length is a hallmark of tumors in 
HNPCC (Peltomaki et al., 1993).  Microsatellites are genomic regions made up of short 
DNA sequences or merely a single nucleotide, often 1 to 5 nucleotides.  The increase or 
decrease in number of DNA repeats in a tumor compared to number of repeats in the 
same region in non-tumor from an individual is referred as ―MSI.‖  In normal cells, the 
misalignment is repaired by caretaker genes. Patients with HNPCC inherit one mutant 
DNA repair gene (―the first hit‖) and one normal allele (Knudson, 2001).   
For unknown reasons, cells in some organs such as colon, stomach and 
endometrium are susceptible to a second, somatic mutation (―the second hit‖), which 
inactivates the normal allele, causing loss of heterozygosity.  The mutation rates are up to 
1000 times higher than normal with homozygous loss of mismatch repair genes, and most 
HNCPP tumors show microsatellite instability.  Most microsatellite sequences are in 
noncoding regions of genes.  However, some microsatellite sequences are located in 
coding or promoter regions of genes involved in cell growth regulation.  These genes 
include type II TGF-β receptor and Bax.  TGF-β signaling inhibits growth of colonic 
epithelial cells, and Bax gene causes apoptosis (Grady, 2004).  Loss of mismatch repair 
results in accumulation of mutations in these and other growth-regulating genes, 
culminating in the emergence of colorectal carcinomas.  
However, lack of any of these proteins in tumors will be inefficient to recognize 
and correct replication errors, thus causing genetic instability.  These proteins contain 
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different efficiencies for recognizing and repairing a wide range of base mispairings 
(Kramer et al., 1984).  For instances, G:T and A:C base mispairings are very efficiently 
corrected, whereas the C:C base mispairing is the worst substrate for mismatch repair.  
These mutations, in some microsatellite regions, cause misalignment of repetitive 
subunits. Germline mutations in mismatch repair genes, predominantly MSH2 or MLH1, 
have been found to cause 90% of cases in patients with HNPCC (Cruz-Correa and 
Giardiello, 2002; Lynch and de la Chapelle, 2003) (Table 1.1).  However, Lynch 
syndrome is less frequently caused by germline mutations in MSH6 and is rarely caused 
by PMS2 (Lynch and de la Chapelle, 2003; Abdel-Rahman et al., 2006) (Table 1.1).  
 
Table 1.1.  The identified mismatch repair genes which cooperated as site of mutation in   
HNPCC. 
Genes Chromosomal location 
Percentage of HNPCC 
mutations detected 
MLH1 3p21 50.9% 
MSH2 2p16 37.6% 
MSH6 2p16 9.6% 
PMS1 2q31 0.3% 
PMS2 7q11 1.6% 
   
 
2.3 Pathogenesis of Colorectal Cancer 
2.3.1 Adenoma-Carcinoma Pathogenesis of Colorectal Cancer 
In the colorectal carcinoma, accumulation of genetic changes underlies 
development of neoplasia.  In the early 90’s, Vogelstein and Fearon (1990) hypothesized 
that colorectal cancer is a multi-step process (Figure 2.3) in which genes are mutated in a 
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specific order (Fearon and Vogelstein, 1990), resulting in the transition from normal 
mucosa to benign adenoma to severe dysplasia to frank carcinoma.  The first in this 
process is loss of APC tumor suppressor gene which results in loss of deleted in colon 
cancer (DCC) gene and activation of K-ras oncogene (Figure 2.3).  This is followed by 
inactivation of p53, leading to eventual carcinoma formation (Figure 2.3).  This is in 
agreement with Knudson’s two hit theory in which carcinogenesis process is thought to 
result from accumulation of two or more mutations that affect cell cycle control 
aberrations or other features of neoplastic development (Knudson, 2001). 
 
 
 
Figure 2.3.  Colorectal cancer occurs in a multi-step process, in which four genes are 
mutated in a specific order.  (Adapted from Baldassarre et al., 2004; Green and Hudson, 
2005) 
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The inactivation or alteration of the APC/β-catenin in Wnt signaling pathway has 
wide spectrum of negative downstream effects with multiple cellular functions and 
interactions, including transcriptional regulation, chromosomal instability, cell migration, 
intracellular adhesion, and regulation of cell cycle, proliferation, differentiation, and 
programmed cell death (Behrens et al., 2005; Jaiswal et al., 2005).  Over the decades, 
development of most colorectal cancers is believed to be initiated by inactivation of one 
APC allele, followed by inactivation of a second APC allele as discussed earlier 
(Knudson, 2001), usually through a mutation or deletion and epigenetic hypermethylation 
in CpG islands of APC promoter region (Hiltunen et al., 1997; Arnold et al., 2004).  
DCC gene located on chromosome 18q21.2 (Fearon et al., 1990), encodes for 
dependence receptors for netrin-1 in colonic and other tissues, thus establishing its role as 
a tumor-suppressor gene in human cancer (Arakawa, 2004; Mazelin et al., 2004).  DCC 
gene product bound to netrin-1 mediates signals for cell proliferation, differentiation, or 
migration (Mazelin et al., 2004).  In the gut, netrin-1 plays a role in mucosal integrity, 
epithelial cell migration, and tissue renewal by inducing cell survival in proliferating 
crypt progenitors (Mazelin et al., 2004; Bredesen et al., 2005).  The netrin-1 level is low 
at the villus tip therefore DCC promotes apoptosis and cell shedding because cell death 
receptors are expressed constitutively throughout crypt-villus axis.  In patients with 
colorectal cancers associated with inflammatory bowel diseases, the anti-apoptotic ligand 
netrin-1 is upregulated causing colorectal cancer to progress (Paradisi et al., 2009).  
Therefore, loss or reduction of DCC expression is proposed to have an important role in 
the transition of an intermediate adenoma to an advanced adenoma (Vogelstein et al., 
1988).  Several reports have suggested that DCC inactivation is a late event in 
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carcinogenesis of colorectal cancer and has a role in metastasis (Itoh et al., 1993; Ookawa 
et al., 1993; Kato et al., 1996).  
The loss of K-ras gene in RAS/RAF signaling pathway and p53 gene are believed 
to be late genetic events in colorectal pathogenesis (Jaiswal et al., 2005).  Among the 
multiple genetic steps in human colorectal carcinogenesis, K-ras mutation is now widely 
considered to be a hallmark of colorectal cancer in humans.  K-ras gene encodes for a 
guanine nucleotide binding protein transmitting signals from membrane-bound tyrosine 
kinases through a group of downstream regulators to the nucleus (Lowy and Willumsen, 
1993).  When a specific mutation occurs in the K-ras gene, the Ras protein is locked in its 
active state (Robbins and Itzkowitz, 2002), activating the signal pathway resulting in an 
unregulated proliferation of colonocytes and transition of adenomas to carcinoma.  K-ras 
point mutations have been detected in about one-half of colon tumors (Forrester et al., 
1987) and in about 60% of colonic aberrant crypt foci in humans (Losi et al., 1996).  K-
ras mutation has also been found in approximately 60% of colon tumors chemically 
induced in rats by DMH or AOM (Jacoby et al., 1991).  Wu and coworkers (2010) 
reported that K-ras induced the growth of HT-29 colon cancer cell line through 
expressions of COX-2, EP1 or EP4, GSK3β and increased Tcf transcriptional factor. 
The p53 has been described as ―the guardian of the genome‖ because of its role in 
maintaining genome stability and integrity by preventing genomic mutations, hence it has 
become one of the most common targets to look for genetic alteration in human tumors 
(Liu and Gelmann, 2002).  Mutations in p53 are believed to play an important role in the 
transition from advanced adenoma to frank carcinoma, with nearly 50% of high-grade 
adenomas and close to 75% of cancers exhibit p53 mutations (Robbins and Itzkowitz, 
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2002).  The p53 tumor suppressor gene located on chromosome 17p13.1 coding for a 
DNA binding protein localized in the nucleus (Liu and Gelmann, 2002).  The major 
functions of the p53 protein are cell cycle arrest and stimulation of apoptosis in response 
to DNA damage such as irradiation, ultraviolet (UV) light, or mutagenic chemicals (Liu 
and Gelmann, 2002).  Activation of normal p53 in response to DNA damaging agents 
leads to cell cycle arrest in late G1 phase and induction of DNA repair by transcriptional 
upregulation of cyclin-dependent kinase inhibitor p21 and the GADD45 genes.  Cells 
proceed with cell cycle if the damaged DNA is repaired successfully; if not, cells with 
mutated DNA are destroyed by induction of apoptosis-inducing genes such as Bax.  In 
cells with homozygous loss of p53, DNA damage is not repaired and accumulates the 
mutation and causes malignant transformation (Liu and Gelmann, 2002). 
2.4 Mouse Models for Colorectal Cancer 
 Rodent and human colons share many biological functions, histological and 
genetic features (Corpet and Pierre, 2005).  Therefore rodent models have been used to 
study mechanisms of carcinogenesis, identification of novel target genes and biomarkers, 
and screen potential chemopreventive agents and their mechanisms of chemoprevention.  
A recent systematic review and meta-analysis of colon chemoprevention in 6,714 human 
volunteers, 3,911 rats, and 458 mice, showed that differences between models was small 
and that rodent models roughly predicted effects in humans, but the prediction is not 
accurate for all agents (Corpet and Pierre, 2005).  These analyses showed that 
carcinogen-induced rat studies matched human trials for aspirin, calcium, carotene, and 
wheat bran whereas Min mice results were comparable with human results for aspirin.   
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Since the environmental factors such as diet strongly influence progression of 
colorectal cancer, efforts were made to generate mice that carry gene mutations 
implicated in progression or initiation of colorectal cancer to study gene-environment 
interactions.  In addition, it is necessary to use carcinogens such as DMH or AOM due to 
extremely low spontaneous rates of colon cancer in laboratory rodents (Corpet and Pierre, 
2005).  Tumors in AOM-induced rats share many histopathologic features with human 
tumors, and in a manner similar to ACF, adenoma, and carcinoma sequences (Takahashi 
et al., 2004).  Colonic tumors induced by DMH or AOM show close similarity in 
histological features and proliferation characteristics to human colonic neoplasms 
(Hamilton et al., 1982).  Therefore, rats exposed to DMH or AOM induced colonic 
tumors are considered a good model to simulate colon carcinogenesis in humans.  
Additionally, the heterocyclic amines such as 2-amino-1-methyl-6-phenylimidazo [4, 5-
b] pyridine (PhIP) have been used to induce tumors in rats and mice through the 
induction of APC and β-catenin mutations in the colon (Tsukamoto et al., 2000).  These 
carcinogen-induced tumors in rodents show an implication of Wnt/β-catenin/Tcf pathway 
during progression of colorectal cancer and over-expression of COX-2 and inducible 
nitric oxide synthase (iNOS) in these tumors (Corpet and Pierre, 2005).  
2.4.1 Mouse Models for Colorectal Cancer and FAP 
 The first mouse that had a mutation in the APC gene was termed multiple 
intestinal neoplasia (APC
Min
) due to its development of more than 100 adenomas in small 
intestine (Su et al., 1992).  These mice were found to have nonsense mutation in the APC 
gene at codon 850 resulting in a truncated protein of 850 amino acids.  APC
Min
 
heterozygotes are born normally but have on average life span of four to six months.  
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Similarly to the APC
Min
 mice, Oshima and coworkers (1995) generated a mouse 
designated APC
Δ716
 which develop multiple adenomas throughout the gastrointestinal 
tract especially in the small intestine, and have a reduced life span.  The use of 
conditional APC allele induces tumors in rat colon instead of small intestine (Shibata et 
al., 1997).  The deletion of a conditional allele APC
580S
 allele leads to development of 
multiple colonic adenomas within four weeks. 
2.4.2 Mouse Models for HNPCC 
 MSH2 was one of the first HNPCC genes to be mutated in mice (Reitmair et al., 
1995).  These mice developed gastrointestinal and skin adenomas and carcinomas.  Fifty 
percent of the MSH2 homozygous mutant mice die by the age of six months and all mice 
die by the age of 12 months.  These mice died early in their life, due to T cell lymphomas 
containing microsatellite instability (Lowsky et al., 1997).  Mice with MSH6 deficiency 
developed invasive B and T cell lymphomas and tumors in gastrointestinal tract; 
however, they did not show microsatellite instability (Edelmann et al., 1997).  Fifty 
percent of the MSH6-deficient mice died by 10 months of age and all of the mice died by 
the 18 months of age.  Therefore, MSH6 homozygous mutant mice have longer life spans 
than that of the MSH2 homozygous mutant mice.  
 The inactivation of MLH1 in mice causes microsatellite instability, infertility, and 
tumor susceptibility (Baker et al., 1996; Edelmann et al., 1996).  MLH-/- mice do not 
produce mature sperm due to prematurely separated chromosomes and arrest in the first 
division of meiosis prior to entering the apoptotic pathway.  MLH1-deficient female mice 
do not produce fertile eggs.  Fifty percent of MLH1-deficient mice died by the age of six 
months and 100% died by 13 months of age, due to the development of T cell 
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lymphomas, gastrointestinal adenomas and early invasive carcinomas, especially in the 
small intestine. 
 In PMS2 deficient mice, the females have normal fertility but not the males, due 
to abnormalities in chromosome synapsis and non homologous pairing during prophase 
of meiosis I (Baker et al., 1995).  PMS-/- mice are prone to have microsatellite instability 
and predisposition to sacromas and lymphomas; however, these mice do not develop 
tumor in their gastrointestinal tract. 
2.5 Chemoprevention of Colorectal Cancer by Dietary Fiber – Phenolic Acids 
2.5.1 Dietary fiber (DF) 
 Dietary fiber is predominantly found in plant-based foods such as vegetables, 
grains, pulses, nuts and fruits (Anderson et al., 2009).  According to Trowell’s original 
definition, dietary fiber is ―that portion of food which is derived from the cellular walls of 
plants which is digested very poorly by human beings‖ (Trowell, 1972).  Over the years, 
the definition of dietary fiber has been discussed at length, to precisely define DF 
constituents.  The American Association of Cereal Chemists (AACC 2001) defined DF as 
―the edible parts of plants or analogus carbohydrates that are resistant to digestion and 
absorption in the human small intestine with complete or partial fermentation in the large 
intestine.  That includes polysaccharides, oligosaccharides, lignin, and associated plant 
substances.‖  The European Commission (2008) has further refined the DF constituents to 
include edible carbohydrate polymers with three or more monomeric units, which are 
neither digested nor absorbed in the human small intestine.  These polymers could be 
obtained from raw or processed food or be synthetic.   
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However, the Codex Alimentarius Committee on Nutrition and Foods for Special 
Dietary Uses (CCNFSDU), the World Health Organization, and the Food and Agriculture 
Organization agreed that carbohydrate polymers with ten or more monomeric units 
should be included in DF (CNFSDU-WHO/FAO Codex Alimentarius Commission, 
2008).   A simplistic DF definition is ―any dietary component that reaches, without being 
absorbed, in a healthy human gut‖ (Ha et al., 2000).  The total dietary fiber (TDF) 
includes soluble dietary fiber (SDF) and insoluble dietary fiber (IDF) based on their 
solubility in water (Asp et al., 1983).  In humans, DF influences human health through 
several mechanisms.  For instance, SDF first acts in the stomach by slowing the transit 
time and reducing the nutrient absorption and the remainder is fermented by microbiota 
in the proximal colon (James et al., 2003).  
2.5.2 The Role of Dietary Fiber in Colorectal Cancer 
The role of dietary fiber in prevention of colon carcinogenesis was first suggested 
by Burkitt (Burkitt, 1970; Burkitt, 1971).  He showed an inverse relationship between 
dietary fiber intake and the risk of colorectal cancer incidence after he observed that 
black Africans had much lower incidence of colon cancer than did Caucasian Africans.  
The former population’s diet was composed mainly of grains and unrefined carbohydrate 
foods while the latter population adhered to Western diet which focused on animal 
protein and contained low amounts of plant-based food.   
Since then, dietary fiber intake has held the interest of scientists due to the 
possibility of being a major factor influencing onset of colon cancer.  The role of DF to 
prevent colon cancer was further reinforced when lower incidence of colon cancer was 
observed in Finnish residents as compared to those in New York (Reddy et al., 1978).  
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Both the populations consumed a high-fat diet, but the Finish group also consumed a 
high-fiber diet.  Over the last three decades, a large body of epidemiological and animal 
studies have proposed that intake of food high in dietary fiber can reduce the incidence of 
colorectal cancer.  Several animal studies indicate a protective effect of dietary fiber.  For 
example, addition of 15% pectin to a semi-purified diet containing 20% fat, inhibited 
AOM-induced tumors in Fischer 344 rats, but it had no corresponding effect on the 
methylnitrosourea (MNU)-induced tumors in rats (Watanabe et al., 1979).  The 
researchers inferred that pectin interferes with the metabolic activation of AOM in the 
colon, which is necessary for carcinogenesis. On the other hand, the addition of 15% 
wheat bran inhibited both AOM- and MNU-induced colon tumors in Fischer 344 rats.  In 
another study, the authors reported that diets containing 35% beef fat and 10% wheat 
bran, alfalfa, or cellulose did not inhibit AOM-induced colon tumors.  Diets with 5% fat 
and 20% or 30% wheat bran or cellulose reduced AOM-induced tumors (Nigro et al., 
1979).  Recently, an epidemiological study showed that daily consumption of 48g of 
whole grain wheat breakfast cereal for three weeks has pronounced a prebiotic effect on 
human gut microbiota (Costabile et al., 2008).  These findings suggest that the type of 
fiber is important in modulating the effects of a colon carcinogen and wheat bran has the 
most consistent inhibiting effect. 
2.5.3 Possible Dietary Fiber-mediated mechanisms in prevention of colon cancer  
Although the mechanisms by which DF reduces the incidence of colon cancer is 
uncertain, it is now widely known that digestion of fibers has several physiological 
effects on the intestinal and colon luminal environment.  The protective effects of DF 
may be mediated by its physical form and its interaction with other dietary components 
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(Kritchevsky et al., 1997).  DF ingestion increases intestinal transit time, which would 
permit less contact time between potential carcinogens in the lumen and in the gut 
mucosa (Burkitt, 1970; Cummings, 1984; Spiller et al., 2003; Vuksan et al., 2008).   
DF also improves concentrations of anti-carcinogenic short-chain fatty acids, and 
augments stool bulk directly, thus diluting potential carcinogens in the large intestine 
(Fleming et al., 1983; Topping and Clifton, 2001; Hawk et al., 2005; Vuksan et al., 
2008).  Bile acids are less soluble at lower pH and therefore there is less conversion of 
primary bile acids to toxic secondary bile acids.  The acidification of the colonic contents 
promote the binding of calcium to free bile acids, thus prohibiting their effects on colonic 
cells (Wargovich et al., 1984).  The increased colonic acidification inhibits colonic 
bacterial enzyme 7α-dehydroxylase which degrades primary bile acids to secondary bile 
acids (Thornton, 1981). 
The possible protective effects of wheat bran include dilution of colonic contents 
(bile acids, long chain fatty acid, and carcinogens), acceleration of colonic transit, 
alteration of energy metabolism by a fermentation product, butyric acid, and promotion 
of microbial growth (Kritchevsky et al., 1997; Lupton and Turner, 1999).  In an animal 
study with Sprague-Dawley, rats fed with a wheat bran diet showed the best dilution 
ability in cecum, proximal, and distal colon.  In the same study, wheat bran was reported 
as the best diluter, followed by cellulose, oat bran, guar gum, pectin, and fiber free diet 
(Gazzaniga and Lupton, 1987).  In another in vivo study with Sprague-Dawley rats, wheat 
bran was shown as the best accelerator of colonic transit, followed by oat bran, pectin, 
guar gum, cellulose, compared to fiber free diet which showed the longest transit time 
(Lupton and Meacher, 1988).  Fiber is metabolized by intestinal microflora with the 
 26 
production of short-chain fatty acids, such as acetate, propionate and butyrate (Scheppach 
et al, 1995; Kritchevsky et al., 1997).  All of the short-chain fatty acids can stimulate 
colonic epithelial proliferation; however, butyrate also has the ability to cause histone 
acetylation, apoptosis induction, differentiation induction, and regulate expression of 
some oncogenes (Scheppach et al., 1995). 
 Epidemiological studies have shown a direct relationship between fecal pH and 
colon cancer incidence in human populations (Bruce, 1987).  Hypothetically, the 
degradation of normal fecal components to potential carcinogens by bacteria may be 
inhibited by increased fecal acidification (Thornton, 1981; Harris and Ferguson, 1993). 
Fiber fermentation by bacteria increases colonic and fecal short chain fatty acid 
production.  Short chain fatty acids, primarily acetate, propionate, and butyrate, are 
organic acids produced within the intestinal lumen by bacterial fermentation of 
predominantly undigested dietary carbohydrates; however, these organic acids are also 
produced in a minor part by dietary and endogeneous proteins such as mucus and 
sloughed epithelial cells (Topping and Clifton, 2001).  Carbohydrate is preferred over 
protein as a substrate for fermentation by most microbes.  Carbohydrate fermentation by 
saccharolytic bacteria occurs mainly in the proximal colon whereas fermentation of 
proteins and amino acids by proteolytic bacteria usually takes place in the distal colon 
where fermentable carbohydrates and water have been depleted (Macfarlane et al., 1992; 
Topping and Clifton, 2001).  Compared to proximal, the distal part of the colon is 
considered less favorable for microbes due to the production of toxic metabolites such as 
ammonia, sulphur-containing compounds, indoles, and phenols as well as the higher pH 
(Topping and Clifton, 2001).  These are some of the reasons which have been suggested 
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for distal colon as the prevalent location of several gastrointestinal disorders such as 
ulcerative colitis and colon cancer (Marteau, 2006; Le Leu et al., 2006).  
The production of short-chain fatty acids also serves as a primary energy source 
for normal colonic epithelium, which contributes to about 5 to 15% of human total caloric 
requirement and stimulates growth of colonic epithelium (Bergman, 1990).  Among the 
short-chain fatty acids, butyrate is the preferred fuel for colonic epithelial cells where 
70% to 90% of butyrate is metabolized by colonocytes (Cook and Sellin, 1998).  Butyrate 
blocks cell cycle at G1 by inducing p21
WAF1/CIP1 
protein which inhibits cell proliferation 
(Archer et al., 1998).  This blockage of cell cycle at G1 might allow DNA checkpoint-
mediated repair of genomic instability or mutations (Scheppach and Weiler, 2004). Fiber 
associated with high butyrate concentrations was shown to reduce tumor mass in 1, 2-
DMH induced tumorigenesis in Sprague-Dawley rats (McIntyre et al., 1993).  In another 
study, short-chain fatty acids such as butyrate induced mitochondrial pathways of 
apoptosis by up-regulating Bcl-2 homologous antagonist killer (Bak) and Bax while 
downregulating Bcl-2 and B-cell lymphoma-extra large (Bcl-xL) in Caco-2 colon cancer 
cells (Ruemmele et al., 2003).  
 Theoretically, the degree of the fiber source protective against colorectal cancer 
development is based on its fermentation ability, which provides higher short-chain fatty 
acid concentrations to maintain the normal colonic cell proliferation and differentiation.    
Besides dietary fiber, phenolic acids have also been shown to prevent colon cancer.   
2.5.4 Phenolic Acids  
 Almost all plants and most of the plant-derived foods contain numerous and 
significant amounts of phenolic compounds, a group of natural products, which includes 
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monomeric cinnamic acids (Herrmann, 1989).  Higher concentrations of these natural 
products are commonly found in cereal bran, the outer protective layers of a cereal grain 
(Baublis et al., 2002).  For example, ferulic acid was found to be one of the major 
phenolic acids in cereal grains, especially in wheat bran (Verma et al., 2009).  Most of 
these phenolic compounds are derivatives of amino acids, phenylalanine or tyrosine, 
followed by deamination and introduction of one or more hydroxyl substituents into the 
phenyl ring to form phenolic acids (Pereira et al., 2009).  There are two major categories 
of phenolic acids in cereal grains: benzoic acid or cinnamic acid derivatives.  These 
compounds are derived from a common carbon skeleton building block: the C6-C1 
benzoic acids and the C6-C3 cinnamic acids (Rice-Evans et al., 1996; Pereira et al., 2009).  
Another difference between the benzoic and cinnamic acid skeleton is the extension of 
the conjugated side chain due to the presence of an additional conjugated double bond in 
cinnamic acid structure.  Benzoic acid is formed by a benzene ring with carboxyl (–
COOH) side chain whereas cinnamic acid has a propenoic (–CH=CH–COOH) side chain 
attached to the benzene ring (Natella et al., 1999).  For example, ellagic and vanillic acids 
belong to benzoic acid derivative phenolic acids while caffeic and ferulic acids belong to 
cinnamic acid derivatives phenolic acids.  The difference in number and position of the 
hydroxyl groups on the aromatic ring contribute to the diversity in structure of phenolic 
acids.  The gallic acid (benzoic acid derivative), has 3 hydroxyl groups on the 3, 4, and 5 
position on the aromatic ring, whereas the ferulic acid (cinnamic acid derivative) has only 
one hydroxyl substitution on the 4 position on the aromatic ring. 
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2.5.5 Wheat – A Major Source of Energy in Human Nutrition 
 Worldwide, wheat is one of the popular cereal grains and a good source of dietary 
fibers (Alabaster et al., 1997).  Phenolic acids are predominantly present in the outer 
protective layer of wheat, the bran layer (Baublis et al., 2002; Gallardo et al., 2006; 
Verma et al., 2009).  The majority of phenolic acids found in a wheat grain exists as 
insoluble and bound forms such as esters, glycosides, and are often conjugated with 
organic acids (Liyana-Pathirana and Shahidi, 2006), whereas a small percentage of 
phenolic acids exists in soluble form (Stalikas, 2007).  Wheat bran extracts exhibit greater 
anti-oxidant capacity than any other wheat grain fractions (Onyeneho and Hettiarachchy, 
1992) and the ability to inhibit lipid oxidation catalyzed through peroxyl radicals (Baublis 
et al., 2000).  More recently, Verma et al. (2009) showed the presence of eleven phenolic 
acids in wheat bran extracts from six Canadian wheat cultivars.  The extracted phenolic 
acids also differed greatly in their anti-oxidant activities.    
2.5.6 Role of Phenolic Acids in Chemoprevention 
Naturally-occurring phenolic acids have been found to be strong anti-oxidants 
against free radicals and/or other reactive oxygen and reactive nitrogen species, which 
often play a role in cancer and cardiovascular diseases (Yu et al., 2002).  The hydroxyl 
derivatives of both benzoic and cinnamic acids act as free radical scavengers, as they 
form a corresponding phenoxyl radical by donating a proton to the radical and 
terminating the radical chain reactions, which breaks the cycle of generation of new 
radicals (Pereira et al., 2009).  The new radical form of the anti-oxidant has a much 
greater chemical stability then the initial radical, and thus these relatively long-lived 
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radicals are able to modify the free radical-mediated oxidation processes (Parr and 
Bolwell, 2002).   
Moreover, phenolic acids are also able to chelate metal ions involved in the 
formation of free radical confers, thus conferring stronger anti-oxidant capacity to 
phenolic acids (Yang et al., 2001; Liyana-Pathirana and Shahidi, 2006).  The 
hydrophobic property of the benzene rings and the hydrogen bonding potential of the 
hydroxyl substituent in phenolic acids, allows them to interact with proteins, and 
therefore act as anti-oxidants, by inhibiting the activities of enzymes involved in free 
radical generation (Shahidi and Wanasundara, 1992; Parr and Bolwell, 2002).  Besides 
anti-oxidant activity, Yoshioka and coworkers (1995) reported that one of the possible 
anti-cancer mechanisms of phenolic acids was mediated through inhibiting AP-1, a 
transcription factor that initiates and promotes tumor growth. 
Phenolic acids have been shown to prevent cancer induction in several 
experimental systems.  In strain-A mice, gallic acid greatly inhibited lung tumors induced 
by chronic treatment with morpholine and sodium nitrite in drinking water (Mirvish et 
al., 1975).  However, gallic acid had a slight inhibitory or no effect on tumorigenesis 
induced by nitrosomorpholine or mono-nitrosopiperazine.  It was suggested that gallic 
acid could be useful as a preventative agent when co-administered with drugs that are 
readily nitrosatable.  The phenolic acids of apples have been linked with prevention of 
colon cancer in vitro (McCann et al., 2007; Eberhardt et al., 2000).  Apple extracts 
inhibited the growth of Caco-2 colon cancer cells in a dose-dependent manner (Eberhardt 
et al., 2000).   
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In HT-29, HT 115, and Caco-2 colon carcinoma cell lines, crude apple extract 
rich in phenolic acids, protected against DNA damage, improved barrier function, and 
inhibited invasion, key stages of carcinogenesis (McCann et al., 2007).  The phenethyl 
ester of caffeic acid was evaluated in the C57B1/6J-Min/+(min/+) mouse model that has 
a germline mutation in the APC gene and is subject to spontaneous intestinal adenomas 
(Mahmoud et al., 2000).  Addition of caffeic acid in the diet reduced tumor formation by 
63% and decreased expression of β-catenin (Mahmoud et al., 2000).  Gallic acid 
treatment in a concentration and time-dependent manner, inhibited the growth of human 
stomach (KATO III) and colon (COLO 205) cancer cell lines through the induction of 
apoptosis (Yoshioka et al., 2000).  This suggested that gallic acid might be useful as an 
adjunct drug for treating digestive tract cancers that are resistant to traditional 
chemotherapeutic agents.  Furthermore, wheat grain orthophenols were shown to prevent 
colon cancer cell growth in Caco-2 cell lines (Drankhan et al., 2003).  In summary, the 
above observations suggest that phenolic acids can be natural alternatives to prevent 
various cancers, especially colon cancer, are the focus of this study.  
2.6 Cyclooxygenase-2 (COX-2)  
2.6.1 Cyclooxygenases (COXs) 
COXs are rate-limiting enzymes in biosynthesis of biological mediators, 
prostaglandins (PGs), which have a variety of physiological effects such as regulation of 
cell proliferation, cell motility, inflammatory mediation, and apoptosis (Sheng et al., 
1998; Stolina et al., 2000; Sheng et al., 2001).  COX-1 gene is mapped to chromosome 
regions 9q32-q33.3 and COX-2 is located on 1q25.2-q25.5, encoding the two isoforms of 
COX-1 and COX-2, respectively (Vane et al., 1998).  
 32 
PGs are formed by oxidative cyclization of central five carbons within 20-carbon 
polyunsaturated fatty acids such as arachidonic acid.  The reaction catalyzed by COX 
includes two key regulatory steps: the enzymatic conversion of the fatty acid to 
prostaglandin G2 (PGG2) and the conversion of PGG2 to prostaglandin H2 (PGH2) by 
COX (Gupta and DuBois, 2001; Howe et al., 2001) (Figure 2.4).  First, two oxygen 
molecules are incorporated into arachidonate to generate PGG2.  In the second step, PGG2 
is reduced to become PGH2 by peroxidase activity of COX-2. PGH2 is then converted to 
one of several PGs, including the PGE2, PGD2, PGF2, PGI2, and thromboxane A2 
(TXA2), through the function of specific PG synthases.   
Two isoforms of COXs have been characterized, COX-1 and COX-2.  COX-1 is a 
housekeeping enzyme which is constitutively expressed in most tissues of body, 
including epithelial cells of the gastrointestinal tract, while COX-2 is not normally 
expressed in most tissues and is not detectable in normal epithelial cells of 
gastrointestinal tract.  The constitutive enzyme, COX-1 has noble housekeeping functions 
such as protecting stomach from ulcers and regulating renal blood flow (Robert, 1983; 
Whelton, 1999).  A wide range of growth factors and pro-inflammatory cytokines in 
specific pathophysiological conditions induce COX-2 which becomes abundant in 
activated macrophages and other cells at sites of inflammation (DuBois et al., 1994).  
Increased COX-2 mediated PGE2 has a strong association with colorectal neoplasia, by 
promoting cell survival, cell growth, migration, invasion and angiogenesis.    
2.6.2 Role of PG in Colon Carcinogensis 
 Increased concentrations of COX-2 decrease intracellular levels of free 
arachidonic acid, thus preventing apoptosis (Prescott and Fitzpatrick, 2000).  COX-2 
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enzymatic activity synthesizes PG which alters cell growth, apoptosis, angiogenesis or 
other mechanisms that lead to cancer. PGE2 treatment of HCA-7 human colon cancer cell 
line reduced cells basal apoptotic rate and concomitant increased cellular levels of Bcl-2 
(Sheng et al., 1998).  PGE2 treatment of another human colorectal carcinoma cell line, 
LS-174, increased cell motility, cell proliferation, and change in colony morphology 
(Sheng et al., 2001).   
 
 
 
Figure 2.4.  Role of COX in prostaglandin synthesis.  The COX catalyse biosynthesis of 
bicylic endoperoxide intermediate PGG2, followed by reduction to PGH2.  PGH2 is then 
converted to one of several PGs, including PGE2, PGD2, PGF2, PGI2, and TXA2, through 
specific PG synthases.  (Adapted from Gupta and DuBois, 2001) 
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This suggested that the PGE2-induced changes in carcinoma cells are associated 
with activation of phosphatidylinositol-3′-kinase (PI3K)/AKT pathway caused by 
activation of PGE2-receptor subtype EP4 (Sheng et al., 2001).  Genetic studies in mice 
suggest that PGE2 promotes tumorigenesis at least in part by activating EP1 receptor 
subtype.  Mice with homozygous deletions in EP1, but not EP3, were partially resistant to 
AOM-mediated induction of aberrant crypt foci (Watanabe et al., 1999; Watanabe et al, 
2000).  Moreover, in AOM-treated wild-type mice, an EP1 receptor antagonist also 
decreased the incidence of aberrant crypt foci.  Finally, Apc
Min
 mice treated with the 
same EP1 receptor antagonist had 57% fewer intestinal polyps than untreated mice 
(Watanabe et al., 1999).  In contrast, studying the genetic role of all four PGE2 receptors 
in development of intestinal polyposis in Apc
Δ716
 mice showed that number and size of 
intestinal polyps was significantly reduced only in mice that harbored a homozygous 
deletion of the EP2 receptor (Sonoshita et al., 2001).  More recently, administration of 
PGE2 to Apc
Min/+
 mice has been demonstrated to increase the size and multiplicity of 
colonic adenomas (Wang et al., 2004).  
2.6.3 Role of COX-2 in Colon Carcinogensis 
Over-expression of COX-2 is a prominent feature in a wide variety of cancers 
including breast and colon (Eberhart et al., 1994; Kargman et al., 1995; Sano et al., 1995; 
Liu and Rose, 1996; Kutchera et al., 1996, Chan et al., 2007).  Over-expression of COX-
2 in colon cancer cells and during inflammatory processes leads to the over-expression of 
PGE2, which can activate E-prostanoid-2 (EP2) receptors, a G-coupled cytoplasmic PG 
receptor (Castellone et al., 2006) (Figure 2.5).  This results in the stabilization and 
accumulation of β-catenin in cytoplasm and its subsequent translocation to the nucleus, 
 35 
where it induces the expression of various target genes regulated by the tcf/lef 
transcription factors.  One of the genes up-regulated by this mechanism is Cyclin D1, 
which is also found to be over-expressed in colon cancer cells, causing cellular 
proliferation (Tetsu and McCormick, 1999).  
COX-2
PGE2
EP2
Gene expression
Cell Growth
 
 
Figure 2.5.  The β-catenin pathway provides a link between COX-2 and colorectal cancer.  
Upon activation of EP2 receptors by PGE2, GTP binds to axin, thus promoting the release 
of GSK-3β from its complex with axin.  This causes the accumulation of β-catenin in 
cytoplasm and its subsequent translocation to nucleus, where it induces the expression of 
various target genes regulated by the tcf/lef transcription factors.  (Adapted from 
Castellone et al., 2006) 
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 Three separate lines of evidences, epidemiological, whole animal pharmacology, 
and in vitro pharmacology, suggest that COX-2 is a rate-limiting step in colon cancer 
carcinogenesis.  Epidemiological evidence shows that individuals who are continuous 
users of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) had 40 – 50% 
decreased mortality from colorectal cancer, suggesting that these drugs may provide a 
chemoprotective effect against colorectal cancer (Kune et al., 1988; Thun et al., 1991; 
Giovannucci et al., 1994; Giovannucci et al., 1995).  In a prospective trial of 635 patients 
with prior resected early-stage colon cancer, use of chronic aspirin for a mean of 12.8 
months showed a 33% reduction of incidence in adenomas compared to control subjects 
(Sandler et al., 2003). 
The effect of decreased incidence of colorectal cancer by regular use of various 
NSAIDs is considered to be by inhibiting COX-2 and, subsequently, prostaglandin 
synthesis which promotes tissue inflammation, cellular proliferation, and tumor growth 
(Clevers, 2006).  Non-selective NSAIDs inhibit both isoforms of COX-1 and COX-2, but 
several selective COX-2 inhibitors have been developed to block the development of 
colonic adenomas and colon cancer (Lichtenstein et al., 1995).  The epidemiological data 
derived from separate studies differing in locale, design, and population have consistently 
shown that regular use of aspirin and other NSAIDs reduce the risk of colon cancer.   
However, there is one important qualification to these studies, as aspirin failed to 
confer any benefit in a randomized trial (Young and Lee, 1999).  This observation raises 
some caution about epidemiological analyses.  Celecoxib, a selective COX-2 inhibitor, 
could both prevent and treat adenomas in Min mouse model of FAP (Jacoby et al., 2000).  
In FAP  patients (n = 77) whose disease carried a germline APC mutation, treatment with 
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Celecoxib (400 mg) twice daily for six months showed a 28% reduction in mean number 
of rectal polyps (Steinbach et al., 2000).  Additional studies have shown that another 
NSAID, Sulindac — a selective COX-2 inhibitor, was also effective in reducing adenoma 
size and number in patients with FAP (Waddell and Loughry, 1983; Giardiello et al., 
1993).  However, the benefits of Sulindac were not as clear in sporadic colon cancer as in 
familial colon cancer (Ladenheim et al., 1995).  These clinical studies support that 
NSAIDs reduce the risk of developing colon cancer and also explain the mechanism 
underlying the clinical observations.  
COX-2 inhibitors are not free of side effects; therefore, COX-2 inhibition cannot 
be used as a long-term chemopreventive strategy.  COX-2 selective NSAIDs have 
potential adverse cardiovascular effects, as first discovered by the Vioxx in 
Gastrointestinal Outcomes Research study.  This report resulted in the withdrawal of 
Rofecoxib, a selective COX-2 inhibitor, as it almost doubled the risk of events leading to 
heart attack or stroke (Malhotra et al., 2004; Graham, 2005).    
 The benefit to risk ratio of a specific NSAID is not conclusive, but there is good 
indication that in selected doses, a NSAIDs can reduce the effects of certain risk factors 
predisposing individuals to colon cancer.  This is supported by research of NSAIDs in 
colon cancer animal models.  The first direct evidence to establish the role of COX-2 in 
inactivation and progression of adenomas was provided by testing the role of COX-2 in 
tumorigenesis in Apc
Δ716 
knockout mouse (Oshima et al., 1996).   
During the first three months after birth, these Apc
Δ716 
knockout mice developed 
hundreds of intestinal polyps.  By incorporating the COX-2 null mutation into Apc
Δ716 
knockout mice, both number and size of polyps in offspring were decreased up to 86% as 
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compared to the control animals.  Moreover, the reduction was in a gene dosage-
dependent manner.  This experiment demonstrated that selective genetic elimination of 
COX-2 protected mice, with a defective APC tumor suppressor, from the development of 
intestinal tumors.  These results were further supported by an observation that a selective 
inhibitor of COX-2, MF tricyclic also conferred protection against colon cancer (Oshima 
et al., 1996).  In conclusion, epidemiological, clinical and animal model studies support 
that COX-2 isoenzyme contributes to pathogenesis in colon carcinogenesis.   
2.7. Programmed Cell Death or Apoptosis 
Apoptosis is a complex process characterized by morphological changes such as 
cell shrinkage, membrane blebbing, chromatin condensation, and nuclear fragmentation 
(Kerr et al., 1972).  Cell number regulation between cell proliferation, survival, and death 
is critical and considered to be one of the important issues for development and 
maintenance of a multi-cellular organism and in particular for colon (Rupnarain et al., 
2004).  Normally, cells divide and multiply in an orderly manner to produce more cells to 
adequately meet the body needs by replacing older cells and maintaining body health.  
Tissue maintenance is a continuous process by which progenitor cells are differentiated 
into specific cell types to perform specialized functions; however, unwanted cells are 
shed into intestinal lumen via apoptosis without affecting neighboring cells (Jones and 
Gores, 1997).  This process of cell death (apoptosis) and regeneration is very tightly 
regulated within intestinal epithelium (Garrison et al., 2009).  Approximately 15 - 25% of 
the colonic and rectal epithelium is rejuvenated everyday and the average time for these 
cells to proliferate is one day.  Moreover, the crypt epithelial cells of the entire colon and 
rectum are replaced every three to four days (Lipkin, 1985).  In mice, as the cells reach 
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villus tip they are shed at a rate of 1,400 cells per villus per day (Potten et al., 1997).  
Therefore, the intestinal epithelium has one of the most rapid turnover rates among 
mammalian tissues.  
In normal colon tissue, stem cells at the bottom of crypts divide continuously in 
an asymmetric manner and cells are added to the crypt’s proliferative zone (Bach et al., 
2000).  These intermediary cells will further differentiate into goblet cells or migrate 
upward to the lumen (Luebeck and Moolgavkar, 2002).  While in malignant tissue, the 
accumulation of genetic changes disrupts normal division, resulting in symmetric division 
that both daughter cells may preserve the clonogenic traits of the stem cell.  This leads to 
stem cells alterations and risk of clonal expansion if apoptotic activity is not adequate 
(Luebeck and Moolgavkar, 2002).  As normal colonocytes develop into cancerous cells, 
there is a change in expression of cell cycle and apoptosis-related proteins (Rupnarain et 
al., 2004). 
2.7.1 Apoptosis-Related Proteins: B-Cell Lymphoma 2 (Bcl-2) Families  
The mechanism for increased cell population is increased cellular proliferation, 
and cell survival or decreased apoptosis.  The proto-oncogene Bcl-2 inhibits apoptosis 
and encourages tumor progression (Sinicrope et al., 1995), the retinoblastoma protein 
(RB) regulates cell cycle progression, and the Bax, Bcl-xL, Fas receptor and Fas-ligand, 
regulate apoptosis and contribute to tumor progression (Backus et al., 2002).  The 
induction of apoptosis is a mechanism to protect against colonic DNA damage 
(Thompson, 1995; Chang et al., 1997).  There is growing evidence that apoptosis plays 
an important role in the regulation of cell number and elimination of harmful cells (Hall 
et al., 1994; ; Tomlinson and Bodmer, 1995; Chang et al., 1997; Potten et al., 1997).  The 
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Bcl-2 family members are intimately involved in apoptosis (Green and Reed, 1998).  
Therefore, apoptosis related proteins of Bcl-2 family have been of interest to researchers 
in colon cancer.   
Bcl-2 family members are classified into three groups based on BH domains, 
mitochondrial anchorage (MA), as well as biological action: pro-apoptotic or anti-
apoptotic (Budd, 2001).  For instance, Bcl-2 and Bcl-xL are anti-apoptotic members 
which have BH1, BH2, BH3, and BH4 domains and a carboxy-terminal hydrophobic trans-
membrane tail domain to localize the proteins to the outer mitochondrial membrane 
(Budd, 2001; Mohamad et al., 2005).  The pro-apoptotic members belong to multi-
domain or BH3-only proteins.  Bax and Bak proteins are multi-domain pro-apoptotic 
members which have BH1, BH2, and BH3 domains and the trans-membrane tail domain 
(Budd, 2001; Mohamad et al., 2005).  In addition, Bid, Bad, and Bim are BH3-only pro-
apoptotic proteins which contain only the BH3 domain and are cytosolic.  BH3-only 
proteins are required to interact with other Bcl-2 family members such as the multi-
domain pro-apoptotic members for oligomerization (Mohamad et al., 2005).  The 
molecular mechanisms inducing apoptosis and cell death differ among the Bcl-2 family 
members due to differences in their structural domains (Reed, 1999).  Bcl-2 proteins are 
present on the outer and inner membrane of the mitochondria where permeability 
transition pores are located (Tsujimoto, 1989; Reed, 1999).  Bax proteins also interact 
with the same contact sites (Reed, 1999). 
The protein members of Bcl-2 family regulate the apoptotic process by promoting 
or inhibiting permeabilization and disruption of outer mitochondrial membranes 
(Mohamad et al., 2005).  Mitochondria release cytochrome c in response to most 
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apoptosis inducers (such as Bid and Bax) and some anti-cancer drugs by opening 
channels in the outer membrane (Shanmugathasan and Jothy, 2000; Adrain and Martin, 
2001).  The change in membrane permeability results in an influx of fluid as well as 
swelling of organelles and eventual rupture of mitochondria (Green and Reed, 1998).  
The release of cytochrome c into cytosol results in activation of apoptosis protease-
activating factor-1 (Apaf-1), which permits binding of adenosine triphosphate (ATP) and 
procaspase 9, and triggers its oligomerization to form an apoptosome (Green and Reed, 
1998; Adrain and Martin, 2001).  The apoptosome cleaves and activates cysteinyl 
aspartate-specific protease 9 (caspase 9) and initiates the activation of executioner 
caspases 3, 6, and 7, thus initiating apoptosis.  The release of cytochrome c can also be 
induced by caspase 8 activated Bid and Bax.  Bcl-2 or Bcl-xL can suppress the effect of 
Bax and Bid by preventing the release of cytochrome c or by interfering with the 
activation of caspase in apoptosome complex.  
In crypts of normal epithelium, Bcl-2 is expressed at the highest level at the base 
and decreases upward along the crypts (McDonnell, 1993), suggesting that the base of 
crypts has the highest rate of cell division through apoptosis prevention while apoptosis is 
stimulated as the cells mature along the crypt (Huerta et al., 2006).  As the colonocytes 
are genetically altered into carcinomas, apoptosis is gradually decreased (Bedi et al., 
1995).  Similarly, compared with a normal colon, the apoptosis events decreased in 
patients with FAP, followed by patients with sporadic adenocarcinomas, and carcinomas 
were found to have the least apoptosis events among the three.  The reduction in 
apoptosis was associated with markedly increased Bcl-2 expression in early carcinomas 
compared with the normal epithelium.  Over-expression of the proto-oncogene Bcl-2 
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could contribute to tumor progression (Sinicrope et al., 1995).  Bcl-2 expression increases 
before the development of morphological dysplasia as Bcl-2 was highly expressed in 
non-dysplasic epithelium adjacent to dysplasic lesions, suggesting that deregulation of 
Bcl-2 is an early event in colorectal carcinogenesis (Hague et al., 1994; Bronner et al., 
1995).  
Bax is a death promoter and it is inactivated in colon cancer (Rampino et al., 
1997; Sturm et al., 1999).  Bax is predominantly localized in cytosol and able to move 
into the outer mitochondrial membrane in response to an apoptotic stimulus (Mandal et 
al., 1998; Mohamad et al., 2005).  In the p53 pathway, Bax is a downstream molecule 
which is mutated in human tumors (Wallace-Brodeur and Lowe, 1999).  Bax gene is 
transcriptionally regulated by p53, and a portion of its tumor-suppressor properties may 
be mediated by the transcriptional activation of the Bax gene (Sturm et al., 1999).  In 
colonic epithelial cells, Bax was found to be highly expressed at the tip of the crypts, 
where apoptosis is active (Krajewski et al., 1994).  More than 50% of colorectal cancers 
with mismatch repair defects have Bax mutations, which abolishes the apoptotic response 
to chemo-preventive agent such as NSAID (Sturm et al., 1999; Zhang et al., 2000b).  The 
decreased level of Bax is a negative prognostic factor for patient mortality with liver 
metastasis and was found to be independent of p53 status (Sturm et al., 1999).  Best 
survival rates were seen in patients with wild type p53 and Bax positive-tumors.  
2.7.2 Apoptosis Mechanisms in the Unstressed and Stress Induced Intestine 
 Apoptosis plays an important role in determining the architecture of intestinal 
epithelia and its stress response to toxic stimuli (Watson and Pritchard, 2000).  Apoptosis 
can be characterized into two broad types: spontaneous apoptosis and stress-induced 
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apoptosis.  Spontaneous apoptosis occurs continuously at low levels in a normal, 
unstressed intestine and regulates the number of cells entering the crypt/villus axis.  
Stress-induced apoptosis occurs after genotoxic treatment such as exposure to gamma 
radiation or DNA-damaging drugs.  
Spontaneous apoptosis occurs at the base of a crypt where epithelial stem cells are 
present and in early transit cells (Watson and Pritchard, 2000).  Mice knockout studies 
have shown that spontaneous apoptosis is independent of p53 and Bax in both small and 
large intestine epithelium (Clarke et al., 1994; Merritt et al., 1994).  Bax and p53 have 
little effect on regulation of normal homeostasis in the gastrointestinal tract.  On the other 
hand, in the colon, homozygous Bcl-2 null C57BL/6 mice showed increased spontaneous 
apoptosis concentrated at the base of a crypt (Merritt et al., 1995).  In another study, the 
morphology of colonic epithelium is normal in Bcl-2
-/-
 mice (Nakayama et al., 1993; 
Nakayama et al., 1994), hence these studies suggest that Bcl-2 plays a role in regulation 
of spontaneous apoptosis in the normal colonic epithelium.  
In contrast, mice knockout (C57BL X DBA/2 F1) studies have demonstrated that 
both p53 and Bcl-2 are important regulators of stress-induced apoptosis with significant 
differences between early and late time points (Clarke et al., 1994; Merritt et al., 1994).  
The p53
-/-
 mice did not show intestinal apoptosis normally observed in p53 wild type 
animals within 3 to 4 hours of gamma radiation damage.  Four and half hours after 40 
mg/kg of 5-fluorouracil administration, Bcl-2
-/-
 mice showed significantly increased 
apoptosis predominantly at the base of the colonic crypts (Pritchard et al., 1999).  In 
contrast to p53 and Bcl-2, Bax plays only a minor part in the regulation of stress-induced 
apoptosis.  In the same study, Bax
-/-
 mice showed no significant difference in apoptotic 
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response in small intestine or mid-colon 4.5 hours after gamma radiation or 5-fluorouracil 
administration as compared with their wild type controls (Pritchard et al., 1999).  
However, a small reduction in apoptotic yield was observed 24 hours after 5-fluorouracil 
intake.  In conclusion, these studies suggest that acute apoptosis is mediated through p53-
dependent pathway in early stages after administration of gamma radiation. 
2.7.3 Regulation of Apoptosis by APC  
Studies of the role of APC in apoptosis for colon cancer have revealed that 
apoptosis activity may be regulated by the inactivation of APC.  In normal human 
colonocytes, APC expression is frequently found in luminal part of crypt where cells are 
shedding from the luminal surface after undergoing apoptosis (Midgley et al., 1997).  The 
induction of wild type APC in an APC mutant cancer cell line increased cell death via 
apoptosis, suggesting that APC plays a role in apoptosis regulation (Morin et al., 1996), 
and the loss of function of APC may cause deregulation of apoptosis in colonocytes.  
2.8 Mitotic Cell Cycle  
Standard eukaryotic cell cycle is divided into four-overlapping phases, with DNA 
synthesis and mitosis occurring during S and M phase, respectively (Figure 2.6).  In G1 
phase and the diploid cell has 2n chromosomes, the cell is growing and it is preparing for 
DNA synthesis (Figure 2.6).  In the subsequent S phase, DNA duplication occurs and at 
the end of this phase, both DNA content and chromosome number will double (4n) 
(Figure 2.6).  Before cells undergo mitosis, they continue in the G2 phase with cell 
growth and are preparing for cell division (Figure 2.6).  During mitosis, separation into 
two daughter cells occurs.  Cells which are in G0 phase (quiescence) are not actively 
cycling.  To avoid inappropriate cell proliferation, control mechanisms are required.  The 
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key regulatory proteins which allow the transition from one cell cycle phase to another 
are called cyclin-dependent kinases, a family of serine/threonine protein kinases which 
are activated at specific points during cell cycle.  Cyclin D1, one of the cyclins is induced 
as the G0 cells are stimulated to enter cell cycle.  Defects in cell cycle regulation can 
result in cancerous growth and developmental abnormalities. 
2.8.1 Role of Cyclin D1 in Cell cycle and Colorectal Cancer 
Cyclin D1 plays an important role in regulating mitosis, especially progression 
from the G1 to S phase of the cell cycle (Arber et al., 1997).  The cell cycle progresses 
when an active complex is formed between Cyclin D1 and its binding partners cyclin 
dependent kinases 4 and 6 (CDK4 and CDK6) through phosphorylation and inactivation 
of retinoblastoma proteins (RB), which results in activation of transcription factor E2F 
(Kato et al., 1993; Han et al., 1999).  E2F can then activate expression of genes involved 
in the S phase progression of cell cycle including cyclin A (Han et al., 1999). 
In late G1 phase, there is a defined restriction checkpoint called R-point, after 
which the cell commits to DNA replication at S phase and finally enters the cell cycle 
(Pardee, 1989).  Before the R-point, cell cycle progression depends on extracellular 
growth factors; however, after passing the R-point, even in the absence of growth factors 
the cell cycle continues (Zetterberg et al., 1995).  Thus, G1 phase is the decision point in a 
cell’s fate: proliferation, temporary arrest or quiescence, differentiation, apoptosis or 
senescence.  In addition, malfunctioning of a protein involved in G1/S regulation could be 
a major cause of malignant transformation.  For instance, in human colon cancer 
malignancies Cyclin D1 transcripts accumulated at the highest level when cells were at 
mid-G1 (Arber et al., 1997). 
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Figure 2.6.  The cell cycle clock machinery.  G0, M, G1, S, and G2 refer to quiescence, 
mitosis, first gap, DNA synthesis, and second gap phases of the cell cycle.  Cell cycle 
restriction points (R-points) regulate the complex network of interactions that determine 
cell growth, cell arrest or apoptosis.  (Adapted from Baldassarre et al., 2004) 
  
In a normal cell, Cyclin D1 expression can be regulated by APC.  Cyclin D1 is 
one of the downstream targets of the APC/Wnt signalling, in which Cyclin D1 expression 
is down-regulated by wild type APC and up-regulated by nuclear β-catenin (Saif and 
Chu, 2010).  In addition, Cyclin D1 gene is a direct target for transactivation by β-
catenin-lef-1 pathway through a lef-1 binding site in the Cyclin D1 promoter (Shtutman 
et al., 1999).  The over-expression of β-catenin caused the induction of Cyclin D1 protein 
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leads to uncontrollable progression into the cell cycle, thus promoting neoplastic 
conversion (Shao et al., 2005).  In contrast, Kazanov et al. (2003) did not observe 
changes in the expression of β-catenin in Cyclin D1 over-expressing cells, indicating that 
Cyclin D1 is downstream to β-catenin and it does not affect its expression.  This could be 
due to nuclear translocation that may have occurred without affecting overall cellular 
concentrations.  
 In several kinds of malignant tumors, such as lung, breast, gastric, esophageal, 
and colon carcinomas, Cyclin D1 genes are over-expressed and hence called as proto-
oncogenes (Arber et al., 1996; Arber et al., 1997; Dobashi, 2005).  A well-characterized 
human colon cancer cell line SW480E8 with high levels of Cyclin D1 when transfected 
with anti-sense CyclinD1 cDNA showed an increase in doubling time; a decrease in 
saturation density, plating efficiency, and anchorage-independent growth; and a loss of 
tumorigenicity in nude mice.  On the other hand, constitutive expression of Cyclin D1 
cDNA increased Cyclin D1 causing abnormal growth and tumorigenicity (Arber et al., 
1997).  Moreover, Cyclin D1 protein is found to be over-expressed in nearly 30% of 
colon adenocarcinomas (Bartkova et al., 1994) and 30% of colon adenomatous polyps 
also show Cyclin D1 over-expression (Arber et al., 1996).  In another study, a non-
tumorigenic intestinal epithelial cell line, IEC-18, when transfected with a vector 
encoding Cyclin D1, resulted in three clones with Cyclin D1 levels similar to that of 
colon cancer cell lines proliferated faster than normal cell lines, demonstrated anchorage-
independent growth in soft agar, higher saturation density and higher plating efficiency.  
These Cyclin D over-expressing clones when injected into nude mice, generated tumors 
within 6-8 weeks (Kazanov et al., 2003).  This study supports that over-expression of 
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Cyclin D1 in normal enterocytes resulted in malignant transformation.  These 
observations suggest that Cyclin D1 over-expression is an early event in colon 
carcinogenesis.  
2.9 Role of Inducible Nitric Oxide Synthase (iNOS) in Colorectal Cancer 
2.9.1 Nitric Oxide Synthase (NOS) 
 The NOS isoenzymes family catalyzes the conversion of terminal guanidine 
nitrogen of amino acid L-arginine to L-citrulline to yield free radical nitric oxide (NO) 
(Moncada et al., 1991).  Three distinct isoforms of the NOS enzymes are identified and 
represent products of three different genes.  Two of the NOS enzymes are termed 
constitutive NOS (cNOS) and are found to be consistently present in the cell while the 
third enzyme is termed inducible NOS (iNOS), which is not typically expressed in resting 
cells, but it is expressed in response to cytokines, microbial products, or 
lipopolysaccharide (Gellar and Billiar, 1998).  Thus, iNOS plays an important role in 
immune response.  One of the cNOS was identified in endothelial cells and thus termed 
as endothelial cNOS (ecNOS) (Garcia-Cardena et al., 1996).  The second cNOS was 
found to be localized to neuronal cells (ncNOS) but it is also found to be present in 
skeletal muscle (Nakane et al., 1993).  cNOS plays a role in regulation of intracellular 
signal transduction pathways, hence maintaining cellular physiology (Moncada et al., 
1991).  Although iNOS and cNOS produce NO, iNOS generates micro-molar 
concentrations of NO which can be sustained over days, compared to the transient, low 
levels of NO generated by the Ca
2+
-dependent ecNOS and ncNOS (Gellar and Billiar, 
1998).  
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NO is a short-lived highly-reactive molecule, rapidly oxidized to form stable, 
inactive end products such as nitrite (NO2) and nitrate (NO3) (Moncada et al., 1991).  The 
cNOS enzymes are calcium-calmodulin dependent for their activation whereas iNOS is 
calcium independent (Moncada et al., 1991).  At high levels of intracellular Ca
2+
, 
calcium-calmodulin binding activates cNOS which generates small amounts of NO, 
which act as messenger molecule and activates soluble guanylate cyclase, thus increasing 
intracellular cGMP (Moncada et al., 1991).  The NO generated by NOS enzymes is a 
potent biological mediator which plays important roles in several physiological and 
pathopysiological functions such as vasodilation, neurotransmission, and immune 
response (Moncada et al., 1991; Gellar and Billiar, 1998).  NO could play a role in 
carcinogenesis due to several reasons.  For example, NO can damage DNA through 
nitrosation of purines and pyrimidines, which results in hydrolytic deamination of 
cytosine to uracil and guanine to xanthine (Nguyen, et al., 1992); it can interfere with 
DNA repair (Jaiswal et al., 2000), and/or cause post-translational modification such as 
nitrosylation potentially leading to tumor initiation and promotion/progression (Liu and 
Hotchkiss, 1995; Wink et al., 1998).  NO has also been shown to cause DNA strand 
breaks and mutations in human cells (Geller and Billiar, 1998).  Thus, the regulation of 
iNOS plays a critical role in colon tumorigenesis. 
2.9.2 iNOS and Colorectal Cancer 
 Recent studies have shown increased iNOS expression and enzymatic activity in 
the breast, head and neck, and colorectal cancers (Thomsen et al., 1995; Gallo et al., 
1998).  The iNOS enzymatic activity was found to be markedly higher in about 60% of 
human colon adenomas and in about 25% of colon carcinomas compared with controls 
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(Ambs et al., 1998).  The iNOS enzymatic activity decreased with increasing tumor 
stages from Dukes A through D and was the lowest in the metastasis to liver and lung.  
Higher iNOS enzymatic activity was found in cancer specimens than in normal mucosa, 
and in metastatic tumors than in nonmetastatic tumors (Cianchi et al., 2003).  These 
findings suggest that iNOS may contribute to the progression of pathogenesis of colon 
cancer at the transition of colon adenoma to carcinoma in situ.  
 NO has both anti-tumor and pro-tumor properties.  The effect of NO may depend 
on the timing, concentration, and tissue type (Wink et al., 1998).  Low concentration of 
NO stimulates cell growth and protects it from apoptosis, whereas high concentrations of 
NO inhibits cell growth and induce apoptosis (Kim et al., 2001).  In contrast, Rao 
suggested that increased activity of iNOS results in inhibition of apoptosis, which is 
mediated through inactivation of caspases, nitrosylation of p53 and NFkB and 
upregulation of COX-2 (Rao, 2004).  Several studies have provided evidence for cross 
talk between COX-2 and iNOS expression and enzyme activities.  NO induced COX-2 
expression has been observed in conditionally immortalized murine colonic epithelial 
cells (Mei et al., 2000).  In animal models of colon cancer, administration of colon-
specific carcinogen AOM increases both iNOS and COX-2 enzyme activities in colonic 
mucosa of F344 rats (Rao et al., 1999; Rao et al., 2002).  Administration of a specific 
iNOS inhibitor, S, S′-1,4-phenylene-bis(1,2-ethanediyl)bis-isothiourea (PBIT), in AOM-
treated F344 rats resulted in a reduction of AOM-induced aberrant crypt formation by 
58% compared with the animals that did not receive the iNOS inhibitor (Rao et al., 
1999).   
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In mice with AOM-induced tumors, when treated with iNOS inhibitor L-N(6)-1-
iminoethyl)lysine tetrazolamide (SC-51) and AG, the number of tumors was reduced 
significantly as compared to non-treated controls.   An even greater reduction in the 
number of tumors was observed with the co-administration of SC-51 and the COX-2 
inhibitor, celecoxib (Rao et al., 2002).  Rats fed with 1-N(G)-nitroarginine methyl ester 
(L-NAME) had a reduction of AOM-induced tumors by 24 to 39% (Kawamori et al., 
2000).  Another iNOS inhibitor 1400W also significant reduced the growth of DLD-2 
colon adenocarcinoma cells that were genetically engineered to express iNOS 
constitutively (Thomsen et al., 1997).  Similarly, knocking out the iNOS gene in APC
Min
 
mice resulted in a marked decreased in the number of intestinal polyps.  In the same 
study, the authors found that administration of the iNOS inhibitor aminoguanidine (AG) 
in drinking water or an L-arginine-deficient diet to APC
Min
 mice resulted in a significant 
decrease in adenoma development (Ahn and Oshima, 2001).  These observations suggest 
that iNOS and NO may play an important role in colorectal carcinogenesis.  Therefore, 
developing iNOS and NO inhibitors for the chemoprevention of colon cancer is a 
mechanistically rational approach.  
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3.0 HYPOTHESES 
1.  Phenolic acids present in wheat bran inhibit the growth of colon cancer cells.  
2.  Colon cancer cell lines can be used to screen the inhibitory effect of phenolic acids.  
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4.0 THESIS OBJECTIVES 
1.  To optimize a cell-culture-based screening system to assess the effects of phenolic 
acids on cell growth. 
2.  To identify molecular markers for regulation of cell growth, pro-apoptosis, and/or 
anti-inflammatory activity for individual phenolic acids used in this study. 
 
This study is based on the assumption that diets rich in wheat bran reduce the 
incidence of colon cancer, thus suggesting that phenolic acids in wheat bran inhibit the 
growth of colon cancer cells.  The present investigation will be limited to study the effect 
of individual phenolic acids on colon cancer cell lines.  Selected diagnostic markers for 
cell growth, pro-apoptosis and anti-inflammatory process will be analyzed to suggest a 
possible mode of action of these phenolic acids in colon cancer prevention.   
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5.0 MATERIALS AND METHODS 
5.1 Chemicals and Reagents 
All chemicals and reagents used in this study were purchased from Sigma Aldrich 
(USA) or otherwise noted. 
5.2 Phenolic Acids Used in This Study 
Eleven phenolic acids previously shown to be present in wheat bran (Verma et al., 
2009) were used in this study.  The diverse phenolic acids are subdivided into two major 
groups based on the side chain attached to the benzene ring (Kim et al., 2006), benzoic 
acids (Figure 5.1) and cinnamic acids (Figure 5.2).  The cinnamic acid derivatives 
include: caffeic, chlorogenic, ferulic, p-coumaric, sinapic, and 3, 4-dimethoxycinnamic 
acids; and the benzoic acid derivatives include ellagic, gallic, protocatechuiv, salicylic, 
syringic, vanillic, 2, 5-dihydroxybenzoic, and 4-hydroxybenzoic acid.   
5.3 Human Colon Cancer Cell Culture and Growing Conditions 
The human colon adenocarcinoma cell lines HT-29 (ATCC Number: HTB-38) 
and HCT 116 (ATCC number: CCL-247) used in this study were obtained from the 
American Type Culture Collection (Rockville, MD, USA).  Both cell lines have 
differences in chromosome numbers and characteristics.  HT-29 is a near triploid (modal 
number of 68 chromosomes) colon cancer cell line with unbalanced translocations and 
deletions as the most frequent alterations (Camps et al., 2004).  HT-29 cells display the 
common chromosomal instability pathway but stable at the microsatellite level (Heinen et 
al., 1995; Camps et al., 2004).  HCT 116 cells are diploid with modal chromosome 
number of 46 and show microsatellite instability phenotype (Heinen et al., 1995; Ribas et 
al., 2003; Camps et al., 2004).  HCT 116 cells carry activating mutation in β-catenin gene 
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and are wild type for APC (Morin et al., 1997), while the undifferentiated HT-29 cells 
express two C-terminal-truncated APC protein of ~100 and 200 kDa (Hsi et al., 1999) 
and are wild type for β-catenin (Heinen et al, 1995; Ilyas et al., 1997).  In addition, HT-
29 cells have normal ras pathway, mutated non-functional p53, low iNOS, and COX-2 
positive.  HCT 116 cells have oncogene K-ras mutation, high iNOS and COX-2 negative. 
HT-29 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) 
(Sigma, USA) containing 1mM sodium pyruvate, 1X non-essential amino acids, and 1X 
vitamins supplemented with 10% (v/v) heat inactivated fetal bovine serum.  HCT 116 
cells were cultivated in McCoy's 5A medium (Gibco, USA) containing 2 mM glutamine, 
10% fetal bovine serum and 1% penicillin and streptomycin.  Both cell lines were 
incubated at 37°C in a 95% humidified atmosphere of 5% CO2 in the air.   
Cells are sub-cultured at pre-confluent densities by using 0.25% trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA) solution.  After the old growth medium 
was aspirated, cells were washed with phosphate-buffered saline (PBS, pH 7.4) solution.  
Eight millilitres of 0.25% trypsin-EDTA solution was added into each flask and swirled 
liquid around for 15 seconds.  After the trypsin-EDTA solution was aspirated, flasks were 
transferred to 37°C incubator for about 5 minutes.  Cells were then observed under a 
reverse-light microscope at the end of the incubation period.  Ten millilitres of complete 
medium with serum was added after gently shaking or tapping the edge of the flask to 
loosen the cells attached at the bottom of the flask. Cells were then re-suspended by 
taking up the medium into a 10 mL sterile pipet several times in order to dislodge the 
cells from the flask.  One milliliter of re-suspended cells was transferred to  
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(a) Ellagic acid 
(4,4',5,5',6,6'-Hexahydroxydipheric acid) 
 
 
(b) Gallic acid 
(3, 4, 5-Trihydroxybenzoic acid)  
 
 
(c) Protocatechuiv acid  
(3, 4-Dihydroxybenzoic acid) 
 
 
(d) Salicylic acid  
(2-Hydroxybenzoic acid) 
 
 
(e) Syringic acid  
(3,5-Dimethoxy-4-hydroxybenzoic acid) 
 
 
(f) Vanillic acid  
(3-Methoxy-4-hydroxybenzoic acid) 
 
 
(g) 2, 5-Dihydroxybenzoic acid  
(Gentisic acid) 
 
 
 
(h) 4-Hydroxybenzoic acid  
(p-Hydroxybenzoic acid) 
 
Figure 5.1.  Chemical structures of benzoic acid derivative phenolic acids used in this 
study. 
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(a) Caffeic acid 
(3, 4-Dihydroxycinnamic acid) 
 
 
 
(b) Chlorogenic acid 
(1, 3, 4, 5-
Tetrahydroxyclohexanecarboxylic acid) 
 
 
 
(c) Ferulic acid 
(Trans-4-hydroxy-3-methoxycinnamic 
acid) 
 
 
 
 
 
 
 
 
 
(d) p-Coumaric acid 
(Trans-4-hydroxycinnamic acid) 
 
 
 
(e) Sinapic acid 
(3, 5-Dimethoxy-4-hydroxycinnamic 
acid) 
 
(f) 3, 4-Dimethoxycinnamic acid 
(Caffeic acid dimethyl ether) 
Figure 5.2.  Chemical structures of cinnamic acid derivative phenolic acids used in this 
study.
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a new flask followed by adding 5 mL fresh complete medium with serum. 
5.4 Cell Culture Based Screening Assay 
5.4.1 Cell Treatment with Phenolic Acid Compounds 
All phenolic acid compounds were dissolved in dimethyl sulfoxide (DMSO) solution, 
except ferulic and vanillic acids, which were dissolved in double distilled water.  For testing, 
HT-29 and HCT 116 cells were seeded at a density of 6 × 10
5 
cells/flask in T-25 cell culture 
flasks with DMEM or McCoy’s 5A medium, respectively.  After 24 hours, growth medium of 
each flask was aspirated and replaced with freshly-prepared complete medium containing 
phenolic acid compound of 0, 10, 100, 200, 400 and 800 μg/mL concentrations.  Three flasks of 
cells were grown for each set of phenolic acid concentration treatment.  In total, there were six 
groups of concentration treatments.  After labeling each flask, flasks were transferred to 37°C 
incubator for 48 hours.  
5.4.2 Cell Harvest and Agar-Cell-Pellet Blocks 
After 48 hours of incubation with phenolic acids, cells’ morphology and percentage of 
confluence were examined under a reverse phase-light microscope.  After discarding the culture 
medium, cells at the bottom of each flask were loosened by using Dulbecco’s phosphate-buffered 
saline (D-PBS, pH 7.4) containing 2 mM EDTA but without Ca
2+
 and Mg
2+
 as the regular 0.25% 
trypsin-EDTA solution would alter the cell morphology or damage the cells prior to 
immunohistochemistry assay.  After 5 minutes incubation in 37°C incubator, 1.5 mL of fresh 
medium were added to each flask and cells were re-suspended by pipetting up and down for 
several times.  The 1.5 mL medium from the first flask were then transferred into the second 
flask of that particular set of concentration treatment and cells were re-suspended again by 
pipetting up and down for several times.   
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The 1.5 mL medium from the second flask was then transferred into the third flask of the 
particular set of concentration treatment and cells were re-suspended by pipetting up and down 
several times.  Cells were collected as much as possible from the third flask and were transferred 
to a new 1.5 mL microcentrifuge tube.  Cells were gently centrifuged down at 450 x g for 3 
minutes and the supernatant was discarded.  In order to mix the cells with 10% melted bactoagar 
better, the microcentrifuge tube was gently flicked with an index finger tip to loosen the cells at 
the bottom.  A sterile transfer pipette was then used to add about 0.3 ml of 10% melted bactoagar 
into each microcentrifuge tube.  Cells and bactoagar were quickly mixed together using a pipette 
tip and were centrifuged for about 10 seconds.  Microcentrifuge tubes were filled with 10% 
buffered formalin solution on top of it and stored overnight at 4°C to fix the cells in the 
bactoagar.  After 24 hours, buffered formalin solution was aspirated and the agar-cell-pellet was 
scooped out from the microcentrifuge tube using a small spatula and placed them on a histology 
cassette lined with tissue paper cut to fit in both sides of a grid of the cassette.  The agar-cell-
pellets were divided with several pieces of normal liver tissues to keep the agar separately and 
aligned in the cassette.  Different tissue color dyes were used to add on the agar-cell-pellets to 
help to maintain the orientation of the agar-cell-pellets.  A cassette was placed in a container 
filled with 10% buffered formalin solution and then embedded with paraffin using standard 
procedures.  Serial 4-μm-thick sections were examined after staining with hematoxylin and 
eosin.    
5.5 Cell Viability 
5.5.1 Trypan Blue Exclusion Method 
The cell viability counting was performed using the Trypan Blue Exclusion method 
(Strober, 1997) and hemocytometer under a reverse light microscope at a magnification of 20X.  
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5.6 Immunohistochemistry Analysis 
5.6.1 Immunohistochemical Staining 
Immunohistochemical staining was performed using Dako autostainer.  Serial 4-μm-thick 
sections cut onto positively-charged slides were examined from the formalin-fixed and paraffin-
embedded agar-cells-pellets, dried, and baked overnight at 60°C.  Slides were deparaffinized 
with xylene and dehydrated by ethanol.  After washing with double-distilled water, sections were 
immersed in freshly-prepared 3% hydrogen peroxide (H2O2) solution dissolved in absolute 
methanol at room temperature for 10 minutes to block endogenous peroxidase activity which 
will cause false positives in staining methods.  The deparaffinized sections were washed three 
times with double distilled water for 5 minutes, and then stored in fresh double-distilled water 
until next step.   
The microwave method was used in the heat-induced epitope retrieval step to ensure the 
removal of cross bridges formed in formalin fixation.  Slides were microwaved in 1mM EDTA 
buffer (pH 9.0) for 13 minutes at power of level 6 (1200W) and cooled in the buffer tray for 20 
minutes.  Slides were placed and cooled under running distilled water to rinse off remaining 
EDTA.  After cooling for another three minutes, slides were immediately used for staining.  
Immunohistochemical staining was performed using Dako autostainer and the Envision plus kits 
and reagents (Dako Canada Inc. ON, Canada).  The sections were incubated with mouse anti-
human Bax monoclonal antibody (Clone 2D2, Thermo Fisher Scientific, Freemont, CA, USA) at 
1:150 dilution; mouse anti-human monoclonal Bcl-2 (Clone 124, Dako Cytomation Inc., 
Carpinteria, CA, USA) at 1:100 dilution; mouse anti-human β-catenin monoclonal antibody 
(clone beta catenin-1; Dako Cytomation Inc., Carpinteria, CA, USA) at 1:200 dilution; mouse 
anti-human COX-2 monoclonal antibody (Clone CX-294; Dako Cytomation Inc., Carpinteria, 
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CA, USA) at dilution 1:50; rabbit anti-human Cyclin D1 monoclonal antibody (Clone SP4, 
Neomarkers Lab Vision, Freemont, CA, USA) at 1:100 dilution; purified mouse anti-human 
iNOS (Clone6/iNOS/NOS type II, BD Transduction Laboratories, Lexington, KY, USA) at 1:40 
dilution or mouse anti-human monoclonal Ki67 (Clone MIB-1, Dako Cytomation Inc., 
Carpinteria, CA, USA) at 1:50 dilution.  Once the staining was completed, slides were 
immediately placed in distilled water and were toned by incubating the slides in 2% copper 
sulphate solution for 5 minutes.  After toning, slides were rinsed quickly with distilled water, 
washed for 5 minutes, and then counter stained with light haematoxylin 1 (10 to 15 dips 
maximum) followed by rinsing with distilled water until slides were completely clear.  Slides 
were then dehydrated by ethanol and stored in final xylene wash until a coverslip was mounted 
onto the sections with a few drops of xylene compatible mounting solution.  
5.6.2 Evaluation of Immunostaining 
After immunostaining, Aperio ScanScope CS Slide Scanner (Aperio Technologies Vista, 
VA, USA) system was used to capture complete slide digital images with a 20X objective.  
Three hundred cells were randomly selected from the scanned slide for immunohistochemical 
analysis.  Staining intensities in each group of cell treatment were evaluated by using the DMSO 
control as internal built-in controls.  The staining intensity and the percentage of tumor cells 
stained were analyzed.  Based on staining intensity, scores were assigned as 0 (negative), +1 
(weak staining), +2 (medium staining), and +3 (strong staining).  Results are scored by 
multiplying the percentage of positive cells by the intensity.  A combined final score was 
obtained by multiplying cell numbers with staining intensity.  
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5.7 Western Blot Analysis 
5.7.1 Sample Preparation and Protein Extraction 
HT-29 and HCT 116 cells were seeded at a density of 6 × 10
5 
cells/flask in six T-25 cell 
culture flasks with DMEM or McCoy’s 5A culture medium, respectively.  After 48 hours 
incubation with test phenolic acid compounds at 0, 10, 100, 200, 400 and 800 μg/ml 
concentrations, the supernatant was removed from each flask.  The attached cells were washed 
twice with 5 ml ice-cold D-PBS solution before protein extraction.  Cells were removed from the 
cell culture flask by gently scraping with a cell-scraper followed by centrifugation of the cell 
suspension for 5 minutes at 450g in a pre-cooled (4°C) centrifuge.  Cellular proteins were 
extracted with the Mammalian Cell Lysis Buffer containing 1 U Benzonase nuclease and 1X 
protease inhibitor (Qiagen, Canada).  Lysates were clarified by centrifugation at 14 000g for 10 
min at 4°C and the supernatant containing cell lysate was transferred into a fresh, pre-cooled 1.5 
ml microcentrifuge tube to be stored at -20°C.  
5.7.2 BCA Protein Quantitation 
Total protein concentration in the samples was determined using a BCA assay kit (Smith 
et al., 1985; Pierce Biotechnology, Rockford, IL, USA). 
5.8 SDS-PAGE and Western Blotting 
Samples containing 10 to 30 μg of total protein were mixed with 10X of sample buffer 
(Laemmli, 1970) containing 2.3% (w/v) SDS, 10% (w/v) glycerol, 5% (w/v) 2-mercaptoethanol, 
0.005% (w/v) bromphenol blue and 62.5 mM tris HCl, pH to 6.8 with HCL (Sigma, UK).  The 
samples were then denatured by heating at 95°C for 4 minutes.  Twelve percent of sodium 
dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate the 
polypeptides, which were subsequently electro-blotted onto polyvinylidene difluoride (PVDF) 
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membrane (Bio-Rad, Mississauga, ON, Canada) in a transblot electrophoretic transfer cell (Bio-
Rad) in transfer buffer.  
5.9 Immunodetection 
After transblotting, the membranes were blocked with 3% (w/v) non-fat dry milk 
(Safeway skimmed milk powder) dissolved in 1X TBST (100 mM Tris pH 8, 150 mM NaCL, 
0.05% Tween 20) for 2 hours at room temperature.  Membranes were incubated with mouse anti-
human Bax monoclonal antibody (Thermo Fisher Scientific, Freemont, CA, USA) at 1:1000 
dilution, rabbit anti-human Cyclin D1 monoclonal (Neomarkers, Lab Vision, Freemont, CA, 
USA) at 1:500 or mouse anti-human β-actin monoclonal antibody (Sigma, USA) at 1:5000 
dilution for overnight at 4°C in a cold room.  After incubation, membranes were washed four 
times for 10 minutes each in Tris-buffered saline, containing 0.05% Tween 20.  The washed 
membranes were incubated with either goat anti-mouse IgG or goat anti-rabbit IgG antibodies 
conjugated with horse radish peroxidase (Santa-Cruz, USA) at 1:1000 dilution for 1.5 hours at 
room temperature.  After incubation, the membranes were washed four times for 10 minutes 
each, and subsequently incubated with luminous ECL Plus reagent (Pierce Chemical, Rockford, 
IL, USA) for 20s and exposed to Kodak X-ray film (Fuji, Japan) for 1s to 10 minutes.  The X-ray 
films were scanned and the densities of the protein bands were analyzed with Adobe Photoshop 
software (version 7.0). 
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6.0 RESULTS 
6.1 Sensitivity of Individual Phenolic Acids on Cell Proliferation 
To develop a cell culture based screening assay for wheat bran constituents, two colon 
cancer cell lines were exposed for 48 hours to individual phenolic acids in concentrations 
ranging from 0 (untreated control) to 800 μg/mL.  Cell viability assessment using Trypan Blue 
Exclusion method showed that in both the cell lines HT-29 and HCT 116 almost all phenolic 
acids reduced cell proliferation in a concentration dependent manner; however, the degrees of 
inhibition were different for each phenolic acid.  
6.2 HT-29 Cell Viability 
Both cinnamic acid and benzoic acid derivatives reduced cell viability at higher 
concentrations; however, cell survival was different for each phenolic acid.  Among the cinnamic 
acid derivatives, caffeic acid at 10 µg/mL reduced cell viability to 38% of untreated cells (Figure 
6.1).  However, increasing concentrations of caffeic acid caused only minor reductions in cell 
viability.  Chlorogenic acid showed a gradual concentration dependent reduction in cell viability 
with only 10% cells were viable at highest concentration (800 μg/mL).  The other four phenolics 
in the cinnamic acid group did not have a significant effect on cell viability at lower 
concentrations; higher concentrations (400 and 800 μg/mL) reduced cell viability to 25 to 40% of 
untreated controls (Figure 6.1).   
In the benzoic acid-derived phenolic acid group, gallic acid reduced cell viability in a 
concentration-dependent manner with only 14% cells being viable at the highest concentration 
(800 µg/mL).  All other phenolic acids only marginally reduced cell growth at lower 
concentrations (10 and 100 μg/mL), except vanillic acid, which at higher concentrations reduced 
cell viability to around 50% of the untreated control cells (Figure 6.2).   
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Figure 6.1.  Effect of cinnamic acid derivative phenolic acids on HT-29 colon cancer cell growth.  
The cell number reduction was expressed as relative percentage and the phenolic acid 
concentrations used were range between 0 and 800 μg/mL. 
 
Figure 6.2.  Effect of benzoic acid derivative phenolic acids on HT-29 colon cancer cell growth.  
The cell number reduction was expressed as relative percentage and the phenolic acid 
concentrations used were range between 0 and 800 μg/mL. 
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6.3 HCT 116 Cell Viability 
Most of the phenolic acids at higher concentrations decreased the growth of HCT 116 cell 
line.  However, compared to HT-29, HT 116 behaved in a different manner, as at lower 
concentrations some of the phenolics stimulated cell survival compared to untreated control 
cells.  In the cinnamic acid-derived group, caffeic acid at 10 μg/mL reduced cell numbers to 
82%; but at 100 μg/mL, only 17% cells survived and at 400 and 800 μg/mL, no viable cells were 
detected (Figure 6.3).  The other phenolic acids in this group at lower concentrations (10 and 100 
μg/mL) did not have inhibitory effect on cell survival or proliferation, but at higher 
concentrations decreased cell number, with the most effect observed at 800 μg/mL.  Sinapic acid 
was the only exception, which at higher concentrations had very little inhibitory effect on cell 
survival or proliferation (Figure 6.3).    
In the benzoic acid derivatives, gallic acid, protocathechuic acid and 2, 5-
dihydroxybenzoic acid significantly increased cell numbers at the lowest concentration (10 
μg/mL) (Figure 6.4).  In gallic acid a sharp decline in cell survival was observed at 100 μg/mL, 
no cells survived and it stayed the same at higher concentrations.  Protocatechuic acid showed 
slight increase at 100 μg/mL, but at 200, 400 and 800 μg/mL the cell numbers gradually reduced 
in a concentration-dependent manner reaching almost zero cell survival at the highest 
concentration.  Ellagic acid showed a gradual concentration-dependent reduction in cell survival 
and at 800 μg/mL no viable cells were detected (Figure 6.4).  All other phenolic acids in this 
group had very little or no effect on cell survival or proliferation.  2, 5-Dihydroxybenzoic acid 
was unique as it showed a sigmoid curve in cell survival and proliferation, at 10 μg/mL a 
significant increase - at 100 μg/mL, a decrease, but again with increasing concentrations gradual 
increase in cell survival and proliferation as compared to untreated control cells (Figure 6.4).    
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Figure 6.3.  Effect of cinnamic acid derivative phenolic acids on HCT 116 colon cancer cell 
growth.  The cell number reduction was expressed as relative percentage and the phenolic acid 
concentrations used were range between 0 and 800 μg/mL. 
 
 
Figure 6.4.  Effect of benzoic acid derivative phenolic acids on HCT 116 colon cancer cell 
growth.  The cell number reduction was expressed as relative percentage and the phenolic acid 
concentrations used were range between 0 and 800 μg/mL. 
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After screening the efficacy of all fourteen phenolic acids on cell survival, proliferation, 
and their effect on expression of protein markers related to cell proliferation, apoptosis, and 
inflammatory pathway, we determined half maximal inhibitory concentration (IC50) for selected 
phenolic acids.  Caffeic and Gallic acids were tested on both the cell lines HT-29 and HT116, 
while ellagic acid with only HCT 116 cells and chlorogenic acid with only HT-29 cells. 
The two phenolic acids, caffeic and gallic acids showed differential effects on both the 
cell lines.  In HT-29 cells, caffeic acid at 10 μg/mL decreased cell viability to 40%, but with 
increasing concentrations did not show any further reductions in cell viability compared to non-
treated controls.  In HCT 116 cells, caffeic acid showed a gradual concentration-dependent 
decrease in cell viability, and at 400 and 800 μg/mL, no viable cells were detected (Figure 6.5).  
On the other hand, with HCT 116 cells, gallic acid (10 μg/mL) showed 20% increase in cell 
viability compared to non-treated control cells, but at 100 μg/mL or higher concentrations, no 
viable cells were detected (Figure 6.5).  HT-29 cells treated with gallic acid showed a 
concentration dependent gradual decrease in cell viability, which at 800 μg/mL showed only 
20% viable cells compared to non-treated control cells (Figure 6.5).  HCT 116 cells were treated 
with ellagic acid and it showed in a concentration-dependent gradual reduction in cell survival.  
Similarly in HT-29 cells, chlorogenic acid showed a gradual concentration-dependent gradual 
decrease in cell survival, and at 800 μg/mL only 40% of cells were viable compared to untreated 
control cells (Figure 6.5). 
6.4 Immunohistochemical Analysis  
To characterize the possible mode of action of phenolic acids in colon cancer prevention, 
phenolic acid-treated cells for both cell lines (HT-29 and HCT 116) were 
immunohistochemically analyzed for seven protein markers: Ki67 and Cyclin D1 for cell 
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proliferation, Bax (pro-apoptotic) and Bcl-2 (cell survival) for apoptosis and COX-2, iNOS, and 
β-catenin for inflammatory pathway.  All the antibodies showed positive reaction with the 
respective proteins, however Bcl2 showed a very weak reaction as compared to the other six 
marker proteins in this study.  Therefore, Bcl-2 was not included for quantitative analysis.  
Representative photographs of histological sections of human colon carcinoma cell line 
HT-29 and HCT 116 treated with chlorogenic acid and ellagic acid respectively were shown in 
Appendix 1 – 12. 
 
 
 
 
Figure 6.5.  The growth inhibitory effect of phenolic acids on HCT 116 and HT-29 cells. 
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6.5 Modulation of Marker Proteins by Cinnamic Acid Derived Phenolic Acids on  
HT-29 Cell Line 
6.5.1 Caffeic Acid 
The two cell proliferation markers, Cyclin D1 and Ki67, both showed slight reductions in 
response to increasing phenolic acid concentration (Figure 6.6).  The reduction was more in 
Cyclin D1 and less in Ki67; however, neither marker showed any significant decrease in staining 
intensity.  The apoptosis marker, Bax showed a gradual concentration-dependent increase in 
expression, increasing to 1.20-fold, 1.55-fold, and 1.82-fold at 10 μg/mL, 100 μg/mL, and 200 
μg/mL of caffeic acid respectively.  Among the three inflammatory markers studied, β-catenin 
and iNOS showed a gradual decrease, with β-catenin levels showing higher reduction than iNOS.  
The COX-2 marker was slightly increased in caffeic acid treated cells, with 100 μg/mL showing 
the most increase.    
6.5.2 Chlorogenic Acid                                                                                    
The cell proliferation marker Cyclin D1 showed a gradual decrease with increasing 
chlorogenic acid concentration, decreasing to 0.81-fold, 0.75-fold, 0.59-fold, and 0.63-fold at 10 
μg/mL, 100 μg/mL, 200 μg/mL, and 400 μg/mL, respectively (Figure 6.7). The Ki67 did not 
show a consistent reduction in expression with increasing chlorogenic acid concentrations.  The 
apoptosis marker Bax increased 1.11-fold, 1.16-fold, 1.44-fold, and 1.47-fold at 10 μg/mL, 100 
μg/mL, 200 μg/mL, and 400 μg/mL of chlorogenic acid.  Among the inflammatory markers, no 
consistent trend was observed in HT-29 cells in response to chlorogenic acid treatment.  The 
very high level of iNOS in response to 200 µg/mL is considered to be an aberration.  
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Figure 6.6.  Effect of caffeic acid on HT-29 cell line. 
  
 
 
Figure 6.7.  Effect of chlorogenic acid on HT-29 cell line. 
 72 
6.5.3 p-Coumaric Acid 
 In HT-29 cells treated with p-coumaric acid, the expression of both the cell proliferation 
markers, Cyclin D1 and Ki67 was reduced in a concentration dependent manner, with Ki67 
showing the highest reduction to 0.29 fold of the control in response to 800 μg/mL (Figure 6.8).  
In cells treated with at 10 μg/mL, 100 μg/mL p-coumaric acid, the apoptosis marker Bax showed 
the most significant increase to 2.0-fold, 2.8-fold, while at higher concentrations of 200 μg/mL, 
400 μg/mL, and 800 μg/mL p-coumaric acid, the increase was more gradual at 3.0-fold, 3.2-fold, 
and 3.4-fold, respectively.  The three inflammatory markers, β-catenin, COX-2 and iNOS 
showed no significant change in their expression in response to p-coumaric acid treatment.   
6.5.4 Ferulic Acid 
Ferulic acid differentially affected the two cell proliferation markers.  Cyclin D1 
expression was significantly decreased in a concentration-dependent manner, only 10% of the 
cells were immune-positive when treated with the highest concentration 800 µg/mL (Figure 6.9).  
Ferulic acid at 10 and 100 μg/mL did not alter Ki67 expression, but at higher concentrations the 
number of immune-positive cells was gradually reduced at higher concentrations, and at 800 
μg/mL only 40% of cells were immunopositive for Ki67.  The apoptosis marker Bax increased in 
a concentration dependent manner, with very high levels of expression (3.5- and 4.5-fold) in 
cells treated with 400 and 800 μg/mL ferulic acid.  The two inflammatory markers, β-catenin and 
COX-2 did not show much variation in response to ferulic acid treatment.  However, iNOS 
expression reduced to 0.85-fold, 0.67-fold, 0.56-fold, 0.53-fold, and 0.46-fold at 10 μg/mL, 100 
μg/mL, 200 μg/mL, 400 μg/mL, and 800 μg/mL of Ferulic acid respectively. 
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Figure 6.8.  Effect of p-coumaric acid on HT-29 cell line.  
 
                                                                    
Figure 6.9.  Effect of ferulic acid on HT-29 cell line. 
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6.5.5 Sinapic Acid 
 The cells treated with sinapic acid (100 and 200 μg/mL) showed a marked increase in 
Cyclin D1 expression and a slight reduction at other concentrations (Figure 6.10).  The other cell 
proliferation marker Ki67 did not show any specific trends in cells treated with Sinapic acid.  In 
HT-29 cells treated with sinapic acid, at the lowest concentration (10 μg/mL) Bax expression 
increased to 1.4-fold, but gradually reduced to 0.7-fold, 0.2-fold, 0.5-fold, and 0.7-fold at 100 
μg/mL, 200 μg/mL, 400 μg/mL, and 800 μg/mL, respectively (Figure 6.10).  Among the three 
inflammatory markers, β-catenin level reduced to 0.9-fold, 0.8-fold, 0.8-fold, 0.8-fold, and 0.8-
fold at 10 μg/mL, 100 μg/mL, 200 μg/mL, 400 μg/mL, and 800 μg/mL of sinapic acid 
respectively (Figure 6.10).  The iNOS expression also reduced to 0.9-fold, 0.8-fold, 0.8-fold, 0.7-
fold, and 0.6-fold at 10 μg/mL, 100 μg/mL, 200 μg/mL, 400 μg/mL, and 800 μg/mL of sinapic 
acid respectively (Figure 6.10).  The COX-2 expression did not change much in response to 
sinapic acid treatment.     
6.5.6 3, 4-Dimethoxycinnamic Acid 
 3, 4-Dimethoxycinnamic acid treated HT-29 cells showed a concentration dependent 
reduction in the two cell proliferation markers Cyclin D1 and Ki67 (Figure 6.11).  At the highest 
concentration (800 μg/mL), both the Cyclin D1 and Ki67 were reduced to 0.4-fold of the 
untreated control cells (Figure 6.11).  Both the apoptosis marker Bax and the inflammatory 
markers, β-catenin, COX-2 and iNOS showed no reduction, except Bax and iNOS which were 
reduced at higher concentrations only (Figure 6.11). 
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Figure 6.10.  Effect of sinapic acid on HT-29 cell line. 
 
Figure 6.11.  Effect of 3, 4-dimethoxycinnamic acid on HT-29 cell line. 
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6.6 Modulation of Marker Proteins by Benzoic Acid Derivative Phenolic Acids on  
HT-29 Cell Line  
6.6.1 Ellagic Acid                                                                                                              
 Ellagic acid treatment of HT 29 cells decreased the expression of both the cell 
proliferation markers Cyclin D1 and Ki67.  However, the decrease was more in Cyclin D1 as 
compared to Ki67 (Figure 6.12).  The Bax expression increased in a concentration dependent 
manner, with the highest concentration (800 μg/mL) showing a 3.1-fold increase over control 
(Figure 6.12).  The three inflammatory markers, β-catenin, iNOS, and COX-2 did not change in 
response to treatment with Ellagic acid. 
6.6.2 Gallic Acid 
Gallic acid at higher concentrations was severely detrimental to cell growth.  Marker 
assays were only possible in cells treated with the lowest concentration (10 μg/mL) of Ellagic 
acid.  The cell proliferation marker Cyclin D1 expression was increased to 1.8-fold, while the 
expression of all other markers either had no effect or showed slight reductions (Figure 6.13). 
6.6.3 Protocatechuic Acid 
 Protocatechuic acid did not show any affect on the cell proliferation markers Cyclin D1 
and Ki67, except at the highest concentration (800 μg/mL), where both Ki67 and Cyclin D 
expression was decreased (Figure 6.14).  However, the inhibitory effect at the highest 
concentration was more pronounced in Cyclin D1 compared to Ki67 (Figure 6.14).  The 
apoptosis marker Bax and inflammatory marker COX-2 did not show any response to treatment 
of cells with Protocatechuic acid.  The other two inflammatory markers β-catenin and iNOS 
showed slight concentration dependent reduce, but the decrease was less compared to Cyclin D1 
(Figure 6.14). 
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Figure 6.12.  Effect of ellagic acid on HT-29 cell line.  
 
 
Figure 6.13.  Effect of gallic acid on HT-29 cell line.  
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Figure 6.14.  Effect of protocatechuic acid on HT-29 cell line.  
 
6.6.4 Salicylic Acid 
 Treatment of HT-29 cells with salicylic acid decreased the expression of both cell 
proliferation markers Cyclin D1 and Ki67, however at higher concentrations of salicylic acid 
Cyclin D1 was reduced more than Ki67 (Figure 6.15).  The apoptosis marker Bax expression 
was significantly increased by almost four fold with the lowest salicylic acid concentration (10 
μg/mL).  There was some variation with higher concentrations, but the increase in expression 
was always more than 3.5-fold.  Among the inflammatory markers, β-catenin was reduced to 0.7-
fold at the lowest salicylic acid concentration (10 µg/mL).  The β-catenin levels did not change 
with increasing salicylic acid concentrations.  Salicylic acid did not affect COX-2 and only 
slightly reduced iNOS levels in HT-29 cells (Figure 6.15). 
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6.6.5 Syringic Acid 
In HT-29 cells, syringic acid treatment in a concentration dependent manner, decreased 
the expression of cell proliferation marker Cyclin D1, while Ki-67 had no effect except at the 
highest concentration (800 μg/mL) (Figure 6.16).  The apoptosis marker Bax was higher than 
controls (1.4- to 1.6-fold) at all syringic acid concentrations except that at 200 μg/mL, it was the 
highest at 2.7-fold more than the control (Figure 6.16).  The β-catenin expression was reduced to 
0.8-fold at 10 μg/mL of syringic acid, however, increasing syringic acid concentration did not 
further reduce β-catenin level significantly (Figure 6.16).  COX-2 expression was also reduced in 
a concentration-dependent manner reaching the lowest level of 0.5-fold compared to controls 
800 μg/mL of syringic acid (Figure 6.16).  The effect of syringic acid on iNOS level did not 
show clear trends.   
6.6.6 Vanillic Acid 
Vanillic acid treatment of HT-29 cells produced a differential effect on the two cell 
proliferation markers analyzed in this study.  Cyclin D1 expression was reduced in a 
concentration-dependent manner, while Ki-67 protein expression was increased by vanillic acid 
treatment at a concentration as low as 10 μg/mL, when it reached 2.3-fold over non-treated 
controls (Figure 6.17).  At higher vanillic acid concentrations, Ki-67 levels were between 1.6 to 
1.9-fold of the non-treated controls (Figure 6.17).  The two inflammatory pathway markers, β-
catenin and COX-2 did not show much change, while at higher vanillic acid concentrations, 
iNOS expression showed a slight decrease compared to non-treated controls (Figure 6.17). 
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Figure 6.15.  Effect of salicylic acid on HT-29 cell line. 
 
 
Figure 6.16.  Effect of syringic acid on HT-29 cell line. 
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Figure 6.17.  Effect of vanillic acid on HT-29 cell line. 
 
6.6.7 2, 5-Dihydroxybenzoic Acid                                                                                                        
Treatment of HT-29 cells with 2, 5-dihydrobenzoic acid decreased the expression of all 
the proteins studied.  The expression of cell proliferation markers Cyclin D1 and Ki67 were both 
reduced, even at the lowest concentrations (10 μg/mL), while at the highest concentration (800 
μg/mL) it was approximately 0.1-fold of non-treated control cells (Figure 6.18).  The apoptosis 
marker Bax was not affected by the 2, 5-dihydroxybenzoic lower concentrations (10 and 100 
μg/mL), but at higher concentrations (800 μg/mL) it was only 0.4-fold compared to non-treated 
controls (Figure 6.18).  The expression of inflammatory markers was reduced in cells treated 
with 2, 5-dihydroxybenzoic acid.  However, the most drastic decrease was in β-catenin and least 
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in COX-2 expression.  iNOS expression was reduced with increasing the 2, 5-dihydroxybenzoic 
acid concentration, but the reduction was much less compared to β-catenin (Figure 6.18).  
6.6.8 4-Hydroxybenzoic Acid 
 Expression of both cell proliferation markers Cyclin D1 and Ki67 was reduced in HT-29 
cells treated with 4-hydroxybenzoic acid.  The most reduction (0.2-fold compared to control) 
was observed in Ki67 in cells treated with the 4-hydroxybenzoic acid highest concentration (800 
μg/mL) (Figure 6.19).  The apoptosis marker Bax showed a concentration-dependent increase in 
cells treated with the 4-hydroxybenzoic acid highest concentration (800 μg/mL) reaching close to 
seven-fold more than the non-treated controls (Figure 6.19).  The three inflammatory markers β-
catenin, COX-2 and iNOS did not show much change in response to 4-hydroxybenzoic acid 
treatment of HT-29 cells. 
 
 
Figure 6.18.  Effect of 2, 5-dihydroxybenzoic acid on HT-29 cell line.  
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Figure 6.19.  Effect of 4-hydroxybenzoic acid on HT-29 cell line. 
 
6.7 Modulation of Marker Proteins by Cinnamic Acid Derivative Phenolic Acids on HCT 
116 Cell Line 
6.7.1 Caffeic Acid                                                                                           
HT 116 cells were treated with three caffeic acid concentrations (10, 100 and 200 μg/mL) 
because at higher concentrations, cells were not viable.  Among the cell proliferation markers, 
Cyclin D1 was reduced to half that in non-treated control cells, while Ki67 concentration did not 
change in response to caffeic acid treatment (Figure 6.20).  An apoptosis marker Bax 
concentration slightly increased with 10 and 100 μg/mL caffeic acid, but when its concentration 
was increased to 200 μg/mL, Bax protein concentration was increased by five-fold (Figure 6.20).  
Among the inflammatory markers, β-catenin showed slight reduction, but iNOS was not 
affected.  The Bcl-2 showed a very weak reaction, therefore it was not quantified.  
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6.7.2 Chlorogenic Acid 
 In response to chlorogenic acid treatment, a cell proliferation marker, Cyclin D1 
expression gradually reduced in a concentration dependent manner, while Ki67 did not show any 
affect (Figure 6.21).  At higher concentrations (200 and 400 μg/mL) of chlorogenic acid, Cyclin 
D1 expression was reduced to 0.5-fold of the control non treated cells (Figure 6.21).  The 
apoptosis marker Bax at all chlorogenic acid concentrations was more than three-fold higher than 
of the non-treated control cells (Figure 6.21).  The two inflammatory markers studied, β-catenin 
showed some reduction in response to chlorogenic acid, but iNOS concentration was similar in 
both treated and non-treated control cells.   
6.7.3  p-Coumaric Acid                                                                                                        
The effect of p-coumaric acid on the presence of two cell proliferation markers is 
inconsistent (Figure 6.22).  Cyclin D1 was slightly reduced at lower concentrations of p-
coumaric acid, but at its higher concentrations it was almost the same as in non-treated control 
cells (Figure 6.22).  Ki67 did not show much reduction at all concentrations of p-coumaric acid 
except at its highest concentration, Ki67 expression was almost half of that in non-treated control 
cells (Figure 6.22).  The apoptosis marker Bax was reduced to half of the non-treated control 
cells at the lowest concentration (10 μg/mL), but it increased to 2.0- to 4.5- fold at all other 
concentrations of p-coumaric acid (Figure 6.22).  Among the inflammatory markers, β-catenin 
showed slight reduction but iNOS did not change in response to p-coumaric acid treatment. 
6.7.4 Ferulic Acid                                                                                                                                                                                       
Ferulic acid treatment at the highest concentration (800 μg/mL) caused some reduction in 
the cell proliferation markers Cyclin D1 and Ki67 which were reduced to almost half the  
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Figure 6.20.  Effect of caffeic acid on HCT 116 cell line. 
 
Figure 6.21.  Effect of chlorogenic acid on HCT 116 cell line.    
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concentration present in non-treated control cells (Figure 6.23).  The apoptosis marker Bax 
increased 1.5-, 1.9-, 2.8-, 2.0-, and 3.1-fold at 10 μg/mL, 100 μg/mL, 200 μg/mL, 400 μg/mL, 
and 800 μg/mL of ferulic acid, respectively, compared to non-treated control cells (Figure 6.23).  
Inflammatory marker β-catenin concentration reduced slightly at lower concentrations of ferulic 
acid treatment but at highest concentration (800 μg/mL) it was only 0.4-fold of non-treated 
control cells of ferulic acid (Figure 6.23).  However, iNOS, another inflammatory marker studied 
did not change in its concentration in response to ferulic acid treatment. 
6.7.5 Sinapic Acid 
 Sinapic acid treatment reduced both the cell proliferation markers Cyclin D1 and Ki67.  
Cyclin D1 concentration decreased gradually and directly in relation to the amount of sinapic 
acid, while Ki67 did not change at most of the sinapic acid concentrations (Figure 6.24).  At 800 
μg/mL sinapic acid both Cyclin D1 and Ki67 were only 0.2-fold of the non-treated control cells.  
The apoptosis marker Bax did not change at10 μg/mL, sinapic acid, but at its higher 
concentrations Bax concentration was 3.0- to 4.8-fold higher than the non-treated control cells 
(Figure 6.24).  The two inflammatory markers β-catenin and iNOS did not show consistent 
variation dependent upon Sinapic acid concentration compared to non-treated control cells.   
6.7.6 3, 4-Dimethoxycinnamic Acid 
 Two cell proliferation markers behaved differently in response to 3, 4-
dimethoxycinnamic acid treatment.  The lowest 3, 4-dimethoxycinnamic acid concentration 
slightly reduced Cyclin D1 concentration, but its expression remained the same as in non-treated 
control cells when cells were treated with increasing 3, 4-dimethoxycinnamic acid concentrations 
(Figure 6.25).  Contrary to Cyclin D1, Ki67 expression was not affected at lower 3, 4-
dimethoxycinnamic acid concentrations, at 400 and 800 μg/mL, Ki67 expression was almost  
 87 
 
Figure 6.22.  Effect of p-coumaric acid on HCT 116 cell line. 
 
Figure 6.23.  Effect of ferulic acid on HCT 116 cell line. 
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Figure 6.24.  Effect of sinapic acid on HCT 116 cell line. 
                                                                                                            
 
Figure 6.25.  Effect of 3, 4-dimethoxycinnamic acid on HCT 116 cell line. 
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two-fold higher than un-treated control cells (Figure 6.25).  The apoptosis marker Bax at the 
lowest concentration (10 μg/mL) increased to almost 2-fold and with increasing concentration 
gradually increased reaching to four-fold higher compared to non-treated control cells (Figure 
6.25). Increasing 3, 4-dimethoxycinnamic acid concentration, gradually reduced β-catenin, by 
0.8- to 0.6-fold compared to non-treated control cells.  iNOS levels were similar to non-treated 
control cells at most of 3, 4-dimethoxycinnamic acid concentrations tested. 
 
6.8 Modulation of Marker Proteins by Benzoic Acid Derivative Phenolic Acids on  
HCT 116 Cell Line 
6.8.1 Ellagic Acid                                                                                                            
 Both the cell proliferation markers were reduced in HCT 116 cells treated with ellagic 
acid. Cyclin D1 was reduced to 0.4-fold even at the lowest concentration (10 μg/mL) of ellagic 
acid, and its increasing concentration gradually reduced Cyclin D1 to almost 10% compared to 
non-treated control cells (Figure 6.26).  Ellagic acid slightly reduced Ki67 expression, except its 
highest (800 μg/mL) concentration, reduced Ki67 to almost 0.4-fold compared to non-treated 
control cells.  Increasing ellagic acid concentrations, gradually increased apoptosis marker Bax 
from 2.0- to 4.5-fold compared to non-treated control cells (Figure 6.26).  Among the two 
inflammatory markers, increasing ellagic acid concentrations, gradually reduced β-catenin from 
0.9- to 0.5-fold compared to non-treated control cells.  At lower concentrations (10, 100 and 200 
μg/mL) of ellagic acid, iNOS was slightly reduced, however ellagic acid (400 μg/mL, reduced 
iNOS to 0.5-fold compared to non-treated control cells (Figure 6.26).  
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6.8.2 Gallic Acid                                                                                                                                                                                                                                                                                                                                                 
 Gallic acid was highly toxic to HCT 116 cells, and sufficient numbers of cells were 
obtained from samples treated with the lowest concentration (10 μg/mL) (Figure 6.27).  All the 
markers were reduced except the apoptosis marker Bax, which showed a slight increase to 1.2-
fold of the non-treated control cells (Figure 6.27).  The inflammatory marker iNOS did not show 
any change in response to gallic acid treatment. 
6.8.3 Protocatechuic Acid                                                                                                          
 All the cell proliferation and inflammatory markers were present in similar amounts in all 
concentrations of protocatechuic acid treated cells or non-treated control cells (Figure 6.28).  
Apoptosis marker Bax at lowest concentration increased slightly, but at higher concentrations 
(100 – 800 μg/mL) varied between 1.9- to 2.5-fold as compared to non-treated control cells 
(Figure 6.28).  
6.8.4 Salicylic Acid                                                                                                               
The two cell proliferation markers studied behaved differently in response to salicylic 
acid treatment.  Increasing concentrations of salicylic acid gradually reduced Cyclin D1 amount, 
with the highest salicylic acid concentration reducing Cyclin D1 to 0.64-fold compared to non-
treated control cells (Figure 6.29).  Ki67 marker increased in response to salicylic acid treatment, 
albeit very little at lower concentrations, but at higher concentrations (400 and 800 μg/mL) it 
increased to 1.7-fold compared to non-treated control cells (Figure 6.29).  The apoptosis marker 
Bax and inflammatory markers β-catenin and iNOS, either did not change or were only slightly 
reduced in amount compared to non-treated control cells (Figure 6.29). 
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Figure 6.26.  Effect of ellagic acid on HCT 116 cell line. 
 
Figure 6.27.  Effect of gallic acid on HCT 116 cell line. 
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Figure 6.28.  Effect of protocatechuic acid on HCT 116 cell line. 
 
 
Figure 6.29.  Effect of salicylic acid on HCT 116 cell line. 
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6.8.5 Syringic Acid 
Syringic acid, in a concentration-dependent manner, reduced the cell proliferation marker 
Cyclin D1 expression compared to non-treated controls (Figure 6.30).  On the other hand, lower 
concentrations of syringic acid did not affect Ki67 amounts, but at higher concentrations (400 
and 800 μg/mL), Ki67 expression was doubled as compared to non-treated control cells (Figure 
6.30).  Syringic acid in a concentration dependent manner increased an apoptosis marker Bax 
from 2.55-fold at lowest concentration (10 μg/mL) of syringic acid and up to 3.6-fold at higher 
concentrations (Figure 6.30).  The inflammatory markers, β-catenin and iNOS showed minor 
variations in response to syringic acid treatment.   
6.8.6 Vanillic Acid                                                                                                                 
 Vanillic acid treatment of cells showed a concentration dependent decrease in Cyclin D1, 
which at the highest vanillic acid concentration, was reduced to 0.4-fold of non treated cells   
(Figure 6.31).  The amount of another cell proliferation marker Ki67 did not show any definite 
trends of reduced amounts in response to vanillic acid treatment (Figure 6.31).  Vanillic acid 
treatment of HCT 116 cells induced large amounts of apoptosis marker Bax, which varied from 
4- to 9-fold higher compared to non-treated cells (Figure 6.31).  The inflammatory markers β-
catenin and iNOS did not show any specific trends in response to vanillic acid treatment (Figure 
6.31). 
6.8.7 2, 5-Dihydroxybenzoic acid 
 Increasing concentrations of 2, 5-dihydroxybenzoic acid treatment of cells reduced a cell 
proliferation marker Cyclin D1 to a low of 0.5-fold compared to non-treated cells (Figure 6.32).  
However, another cell proliferation marker Ki67 did not change much at lower concentrations of 
2, 5-dihydroxybenzoic acid treatment, but at its highest concentration, Ki67 was reduced to 
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almost 0.3-fold of non-treated cells (Figure 6.32).  2, 5-Dihydroxybenzoic acid treatment of HCT 
116 cells increased an apoptosis marker Bax. Increasing concentrations, of 2, 5-
dihydroxybenzoic acid, up to 200 μg/mL, Bax gradually increased to 5-fold compared to non-
treated cells (Figure 6.32).  However, at higher concentrations (400 and 800 μg/mL) of 2, 5-
dihydroxybenzoic acid, Bax was reduced to 1.8- and 1.2-fold compared to non treated cells 
(Figure 6.32).  Among the two inflammatory markers, β-catenin did not show any change in 
response to 2, 5-dihydroxybenzoic acid treatment, while iNOS showed some reduction compared 
to non-treated cells. 
6.8.8 4-Hydroxybenzoic acid                                                                                                              
 HCT 116 cells treated with 4-hydroxybenzoic acid reduced the amount of cell 
proliferation marker Cyclin D1, which at the highest concentration (800 μg/mL, 4-
hydroxybenzoic acid) was reduced to 0.3-fold compared to non treated cells (Figure 6.33).  
However, another cell proliferation marker Ki67 did not change or show much reduction in 
amount compared to non-treated cells (Figure 6.33).  4-Hydroxybenzoic acid treatment of cells 
increased an apoptosis marker Bax compared to non treated cells, except in cells treated with the 
highest (800 μg/mL) concentration (Figure 6.33), where it was in similar quantities as in non 
treated cells (Figure 6.33).  In HCT 116 cells, 4-hydroxy benzoic acid treatment, inflammatory 
markers β-catenin and iNOS did not show much change compared to non treated cells, except 
high concentrations (400 and 800 μg/mL), iNOS was reduced to 60% of non treated cells (Figure 
6.33). 
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Figure 6.30.  Effect of syringic acid on HCT 116 cell line. 
 
 
Figure 6.31.  Effect of vanillic acid on HCT 116 cell line. 
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Figure 6.32.  Effect of 2, 5-dihydroxybenzoic acid on HCT 116 cell line.  
 
 
Figure 6.33.  Effect of 4-hydroxybenzoic acid on HCT 116 cell line. 
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6.9 Western Blot Analysis 
 To confirm the results of immunohistochemical studies, we performed Western Blot 
analysis using crude cell extracts prepared from cells treated with selected individual phenolic 
acids. Caffeic, ellagic, and gallic acids were used for confirmatory assays using HCT 116 cell 
line, while caffeic, gallic, and chlorogenic acid was used with HT-29 cell line.  Apoptosis marker 
Bax and cell proliferation marker Cyclin D1, both of which showed the highest degree of 
variation in immunohistochemical assays were used to confirm the results using western blot 
analyses.  Polyclonal antibodies against β-actin were used as internal standard to normalise the 
amount of proteins loaded on to SDS-PAGE gels for analyses. 
All the antibodies reacted with respective polypeptides (Figures 6.34 – 6.37).  Significant 
variation in reaction was observed with polypeptide specific antibodies, but as expected β-actin 
antibodies showed very similar reaction with all cell extracts in respective treatment.  This 
suggests that similar amounts of protein were loaded on the gels in respective treatments.  A 
quantitative estimation was made by quantifying the band intensity and comparing the intensity 
with non-treated control cells (Appendix 13).  In HCT 116 cells, caffeic and ellagic acid 
treatments showed an increase in Bax polypeptide, with highest increase of 3.5-fold was 
observed with 200 µg/mL caffeic acid (Figure 6.38).  Gallic acid was highly toxic to cells and 
viable cells were obtained only at 10 µg/mL, and at this concentration Bax polypeptide band 
intensity did not differ from untreated control cells.  Cyclin D1 band intensity was decreased in 
all treatments, with most decrease observed 400 µg/mL ellagic acid (Figure 6.38).    
In HT-29 cells, caffeic acid and chlorogenic acid increased the band intensity of Bax 
polypeptides.  The highest concentration (800 µg/mL) of chlorogenic acid increased Bax 
polypeptide intensity by more than three-fold (Figure 6.39).  Viable cells were obtained with 
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only 10 µg/mL gallic acid, at which the Bax polypeptide intensity did not differ from untreated 
control cells.  Caffeic acid at the lowest concentration (10 µg/mL) drastically reduced the 
intensity of Cyclin D1 immunoreactive band.  Both chlorogenic acid and gallic acid treatment 
showed some reduction in Cyclin D1 immunoreactive band intensity (Figure 6.39).  
 
 
 
(a)  
(b)  
(c)  
(d)  
(e)  
(f)  
 
 
Figure 6.34.  Western blotting analysis to detect pro-apoptotic Bax in phenolic acid treated and 
untreated HCT 116 cells.  HCT 116 cell line was incubated with (a) caffeic acid, (c) ellagic acid, 
and (e) gallic acid at 0 to 800 μg/mL phenolic acid concentrations repectively.  (b, d, and f) The 
level of β-actin in each sample was detected by a polyclonal anti-actin antibody (Sigma, UK).  β-
actin was used as internal standard to ensure the equal amounts of protein was loaded.  Lane 1: 0 
μg/mL, lane 2: 10 μg/mL, lane 3: 100 μg/mL, lane 4: 200 μg/mL, and lane 5: 400 μg/mL of 
caffeic, ellagic or gallic acid.  kDa, molecular weight in thousands. 
 
 
 
Lane         1              2               3              4                 5                
- Bax, 23 kDa 
- β-actin, 43 kDa 
- β-actin, 43 kDa 
- Bax, 23 kDa 
- β-actin, 43 kDa 
- Bax, 23 kDa 
 99 
 
 
(a)  
(b)  
(c)  
(d)  
(e)  
(f)  
 
 
Figure 6.35.  Western blotting analysis to detect Cyclin D1 in phenolic acid treated and untreated 
HCT 116 cells.  HCT 116 cell line was incubated with (a) caffeic acid, (c) ellagic acid, and (e) 
gallic acid at 0 to 800 μg/mL phenolic acid concentrations.  (b, d, and f) The level of β-actin in 
each sample was detected by a polyclonal anti-actin antibody (Sigma, UK).  β-actin was used as 
internal standard to ensure the equal amounts of protein was loaded.  Lane 1: 0 μg/mL, lane 2: 10 
μg/mL, lane 3: 100 μg/mL, lane 4: 200 μg/mL, and lane 5: 400 μg/mL of caffeic, ellagic or gallic 
acid.  kDa, molecular weight in thousands. 
 
 
 
 
 
 
 
Lane         1               2              3                4                 5                 
- Cyclin D1, 36 kDa 
- β-actin,  43 kDa 
- Cyclin D1, 36 kDa 
- β-actin,  43 kDa 
- β-actin, 43 kDa 
- Cyclin D1, 36 kDa 
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Figure 6.36.  Western blotting analysis to detect pro-apoptotic Bax in phenolic acid treated and 
untreated HT-29 cells.  HT-29 cell line was incubated with (a) caffeic acid, (c) chlorogenic acid, 
and (e) gallic acid at 0 to 800 μg/mL phenolic acid concentrations.  (b, d, and, f) The level of β-
actin in each sample was detected by a polyclonal anti-actin antibody (Sigma, UK).  β-actin was 
used as internal standard to ensure the equal amounts of protein was loaded.  Lane 1: 0 μg/mL, 
lane 2: 10 μg/mL, lane 3: 100 μg/mL, lane 4: 200 μg/mL, lane 5: 400 μg/mL, and lane 6: 800 
μg/mL of caffeic, chlorogenic or gallic acid.  kDa, molecular weight in thousands. 
 
 
 
 
 
 
 
Lane        1                 2                3                 4               5               6 
- Bax, 23 kDa 
- β-actin, 43 kDa 
- β-actin, 
43 kDa 
- Bax, 
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- Bax, 23 kDa 
- β-actin, 43 kDa 
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Figure 6.37.  Western blotting analysis to detect Cyclin D1 in phenolic acid treated and untreated 
HT-29 cells.  HT-29 cell line was incubated with (a) caffeic acid, (c) chlorogenic acid, and (e) 
gallic acid at 0 to 800 μg/mL phenolic acid concentrations.  (b, d and, f) The level of β-actin in 
each sample was detected by a polyclonal anti-actin antibody (Sigma, UK).  Β-actin was used as 
internal standard to ensure the equal amounts of protein was loaded.  Lane 1: 0 μg/mL, lane 2: 10 
μg/mL, lane 3: 100 μg/mL, lane 4: 200 μg/mL, lane 5: 400 μg/mL, and lane 6: 800 μg/mL of 
caffeic, chlorogenic or gallic acid.  kDa, molecular weight in thousands. 
 
 
 
 
 
 
 
 
 
 
 Lane          1                2                3                4               5               6 
- Cyclin D1, 36 kDa 
- β-actin,  43 kDa 
- β-actin, 43 kDa 
- Cyclin D1, 36 kDa 
- Cyclin D1, 43 kDa 
- β-actin, 43 kDa 
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Figure 6.38.  Relative quantitation of Western Blot of cell treatments from human colon cancer 
cell line HCT 116 probed with primary antibody against Bax or Cyclin D1. 
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Figure 6.39.  Relative quantitation of Western Blot of cell treatments from human colon cancer 
cell line HT-29 probed with primary antibody against Bax or Cyclin D1. 
 
 
 
 
 
 
 
 
 
 
 
 
Bax Cyclin D1 
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7.0 DISCUSSSION 
Eleven phenolic acids used in this study have been shown to be present in wheat bran 
from six wheat cultivars belonging to six market classes (Verma et al 2009).  Gallic and Ellagic 
acids show high anti-oxidant activities and chlorogenic acid is a metabolic product of caffeic 
acid, therefore, the three phenolic acids were also included in the study.  The phenolic acids 
differed in their anti-oxidant potential as measured by the discoloration of 2, 2-diphenyl-1-
picrylhydrazyl (DPPH) (Beta et al., 2005) or 2, 2’-azino-bis(3-ethylbenzothiazone-6-sulphonic 
acid) (ABTS) discoloration (Trolox) equivalent anti-oxidant capacity (TEAC) assay (Re et al., 
1999).    
7.1 Two Different Human Colon Cells Were Used for the Study 
One of the objectives of this study was to assess the utility of an in vitro cell culture-
based screening assay to evaluate the efficacy of wheat bran phytochemicals in cancer 
prevention.  The two human colon adenocarcinoma cell lines HT-29 and HCT 116 used in this 
study are different and have distinct advantages to indicate the molecular mechanism underlying 
colon cancer prevention by phenolic acids used in this study (Table  7.1).   
7.2 Differential Growth Inhibitory Effects of Individual Phenolic Acids on HT-29 and HCT 
116 Cell Lines  
The individual phenolic acids differed in their ability to prevent the human colon cancer 
cell growth in HCT 116 and HT-29 as determined by calculating the half maximal inhibitory 
concentration (IC50; mM) of phenolic acids at which only 50% of the cell survived.  The 
effectiveness of individual phenolic acids to inhibit cell growth was divided into three categories: 
highly effective (IC50 ≤ 1 mM), moderately effective (IC50 between 1 and 3 mM), and least 
effective (IC50  ≥ 3 mM).  For HT-29 cells the IC50 varied from as low as 0.06 mM for caffeic 
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acid to a high of 2.90 mM for salicylic acid (Figure 7.1).  On the other hand for HCT-116 cell 
line, the IC50 values ranged from 0.15 mM for gallic acid to 5.79 mM for 4-hydroxybenzoic acid 
(Figure 7.2).  Compared to benzoic acid derivatives, cinnamic acid derivatives had lower IC50 in 
both the cell lines, thus suggesting that these are more effective in inhibiting the growth of colon 
cancer cells.  The growth of HCT 116 cells was inhibited the most by caffeic, ellagic, and gallic 
acids with IC50 of 0.22 mM, 0.17 mM, and 0.15 mM, respectively (Figures 7.2).  On the other 
hand, to prevent the growth of HT-29 cells, caffeic, chlorogenic, and gallic acids are most 
effective, with IC50 at 0.06 mM, 0.28 mM, and 0.30 mM, respectively (Figure 7.1). 
 
Table 7.1.  Distinguishing characteristics of human colon cancer cell lines HT-29 and HCT 116 
used in this study. 
 
HT-29 HCT 116 
Near triploid (modal chromosome number 
68) 
Diploid  (modal chromosome number 46) 
Frequent unbalanced chromosomal 
translocations and deletions 
None observed   
Display chromosomal instability pathway 
but stable at microsatellite level 
Display chromosomal stability but show 
microsatellite instability 
Normal β-catenin Activating mutation in β-catenin gene 
Exhibit two C-terminal-truncated  APC 
protein of ~100 and 200 kDa 
Wild type for APC 
Normal ras pathway K-ras mutation 
Mutated non-functional p53 Normal p53 
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Figure 7.1.  The half maximal inhibitory concentration (IC50) of individual phenolic acids on HT-
29 colon cancer cell line. 
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Figure 7.2.  The half maximal inhibitory concentration (IC50) of individual phenolic acids on 
HCT 116 colon cancer cell line. 
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 7.3 Differential Effect of Phenolic Acids on Markers for Colon Cancer 
 A statistical analysis revealed that in both the cell lines HT-29 and HCT-116,  phenolic 
acids differentially affected markers for cell proliferation, apoptosis, and cell inflammation.  In 
general the phenolic acid treatment negatively correlated with cell proliferation and 
inflammatory markers, but positively correlated with apoptosis marker Bax (Table 7.2).  Among 
the benzoic acid derivatives, ellagic acid, vanillic acid and 2, 5-dihydroxybenzoic acids showed 
highly significant (p < 0.01) negative correlations with the cell proliferation marker Ki67 (Table 
7.2).  In the cinnamic acid derivatives, caffeic acid, chlorogenic acid and ferulic acid showed 
highly significant negative correlation with Ki67 (Table 7.2).  Ellagic acid, caffeic acid, 
chlorogenic acid and p-coumaric acid were significantly (p < 0.01) negatively correlated with 
inflammatory marker β-catenin (Table 7.2).  However only caffeic acid and chlorogenic acid 
were highly significantly-correlated with another inflammatory marker iNOS (Table 7.2).  COX-
2 marker did not reveal statistically significant correlations with any of the phenolic acids tested.  
An apoptosis marker Bax was in general positively correlated with phenolic acid treatment of 
cells.  Ellagic and ferulic acids were significantly (p < 0.01) positively correlated with Bax 
marker (Table 7.2).  These results suggest that phenolic acid treatment may promote apoptosis 
and reduce cell proliferation and inflammation.  Ellagic acid, gallic acid, caffeic acid, 
chlorogenic acid and ferulic acid showed at least one marker statistically significant in all the 
three processes studied (cell proliferation, apoptosis and inflammatory) and will be discussed in 
the following sections. 
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Table 7.2.  Correlation coefficients to see the effects on both the cell lines together.  (Pearson 
correlation were used to determine the effects; * represents p < 0.05; ** represents p < 0.01) 
 
Phenolic acid 
Cell 
number 
Markers 
Cell 
Proliferation 
Apoptosis Inflammatory 
Cyclin 
D1 
Ki67 Bax 
β- 
catenin 
COX-
2 
iNOS 
Benzoic Acid Derivatives  
Ellagic Acid -0.46 -0.39 -0.90** 0.72** -0.74** -0.02 -0.57 
Gallic Acid -0.62* -0.45* -0.58* -0.59* -0.61* -0.39* -0.62* 
Protocatheuic Acid -0.47 -0.10 -0.58* 0.20 -0.32 -0.03 -0.44 
Salicylic Acid -0.72** -0.18  0.15 0.20 -0.61* -0.02 -0.56 
Vanillic Acid -0.25 -0.17 -0.91** -0.39 -0.42 -0.05 -0.63* 
2, 5-Dihydroxybenzoic 
Acid 
-0.25 -0.17 -0.91
** 
-0.39 -0.42 -0.05 -0.63
* 
4-Hydroxybenzoic 
Acid 
-0.68
* 
-0.40 -0.25 0.55 -0.34 -0.05 -0.36 
Cinnamic Acid Derivatives 
Caffeic Acid -0.57 -0.57 -0.84** -0.55 -0.87** -0.43 -0.87** 
Chlorogenic Acid  -0.69* -0.51 -0.90** -0.45 -0.88** -0.39 -0.83** 
p-Coumaric Acid -0.48 -0.03 -0.53 0.45 -0.72** -0.03 -0.43 
Ferulic Acid -0.61* -0.27 -0.94** 0.71** -0.65* -0.03 -0.51 
Sinapic Acid -0.37 -0.49 -0.54 0.05 -0.26 -0.02 -0.69* 
3, 4-
Dimethoxycinnamic 
Acid 
-0.71
** 
 0.01  0.08 0.44 -0.55 -0.03 -0.62
* 
 
 
 110 
 7.4 Ellagic Acid Affects Cell Proliferation, Apoptosis and Inflammatory Markers 
Ellagic acid is a naturally occurring dietary phenolic acid which demonstrates a variety of 
anti-carcinogenic activities (Barch et al., 1996) and has been shown to reduce the risk of a 
number of carcinogen-induced tumors (Lesca, 1983; Mukhtar et al., 1984; Mandal and Stoner, 
1990) through a number of different mechanisms (Mukhtar et al., 1984; Dixit et al., 1985; Dixit 
and Gold, 1986; Barch and Fox, 1988; Puchalski and Fahl, 1990; Barch and Rundhaugen, 1994; 
Barch et al., 1995).  Ellagic acid is present in several berries, fruits and nuts including 
pomegranates and red berries such as raspberries, strawberries, and walnuts (Narayanan et al., 
1999; Clifford and Scalbert, 2000; Fjaeraa and Nånberg, 2009).  Ellagic acid is normally 
conjugated with a glycoside moiety such as glucose, arabinose, xilose and also forms part of 
polymeric molecules called ellagitannins (Clifford and Scalbert, 2000; Espín et al., 2007).  In 
humans, ellagic acid is formed by hydrolysis of ellagitannins via lactonisation of 
hexahydroxydiphenic acid, and it is further metabolized by colonic microorganisms to yield 
urolithins which are more lipophilic (Clifford and Scalbert, 2000; Espín et al., 2007).  Thus, 
ellagic acid is more readily absorbed over the intestinal mucosa into circulation.  
Ellagic acid induces the expressions of phase II detoxification enzymes glutathione S-
transferase (Barch et al., 1995) and NAD(P)H:quinine reductase (Barch and Rundhaugen, 1994).  
In addition, ellagic acid can also bind to DNA and inhibit the formation of O
6
-methylguanine by 
methylating carcinogens (Dixit and Gold, 1986; Barch and Fox, 1988).  This effect is consistent 
with the induction of O
6
-methylguanine-DNA methyltransferase (MGMT) which rapidly 
removes AOM-induced promutagenic O
6
-methylguanine DNA adducts and thus prevents 
oncogenic G to A point mutations (Zaidi et al., 1995; Pegg and Byers, 1992).  There is growing 
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evidence that select mutagenic and lethal lesions involve the O
6
 position of guanine (Sancar, 
1995).   
Functional groups of ellagic acid may play a role in its anti-carcinogenic activities (Barch 
et al., 1996).  For example, the lactone groups are required to induce phase II enzymes and 
reduce carcinogen-induced formation of O
6
-methylguanine, whereas both the 3- and 4-hydroxyl 
groups of ellagic acid are required to directly detoxify benzo[a]pyrene diolepoxide.  Ellagic acid 
also shows anti-proliferative activity by inducing cell cycle arrest and/or apoptosis in several 
human cancer cell lines such as bladder T24, cervical carcinoma CaSki, leukemia MOLT-4, 
breast MCF-7, prostate DU 145, and colon cancer Caco-2 cells (Narayanan et al., 1999; Losso et 
al., 2004; Li et al., 2005; Mertens-Talcott et al., 2005; Larrosa et al., 2006).  Ellagic acid showed 
differential anti-proliferative activity in Caco-2, MCF-7, and DU 145 cells, with Caco-2 cells 
were the most sensitive cells followed by DU 145 and MCF-7 cells (Losso et al., 2004).  The 
anti-carcinogenic effect of dietary ellagitannins could be mainly due to their hydrolysis product, 
ellagic acid, which induced cell-cycle arrest as well as apoptosis via mitochondrial pathway in 
Caco-2 colon cancer cells (Larrosa et al., 2006).  Ellagic acid treatment of Caco-2 cells 
downregulated cyclin A and B1 and upregulated cyclin E and arrested cell cycle in the S phase.  
In this study, ellagic acid showed the strongest inhibitory effect on HCT 116 cells, with 
IC50 = 0.17 mM.  In both the cell lines HT-29 and HCT 116, ellagic acid upregulated Bax and 
downregulated Cyclin D1 and β-catenin and iNOS proteins in a concentration dependent manner.  
This suggests that ellagic acid reduced cell proliferation and inflammatory pathways but 
promotes apoptosis.   These results concur with those obtained with crude pomegranate fruit 
extract, containing ellagic acid among others, inhibited cell growth and induced apoptosis in a 
dose dependent manner in androgen-insensitive prostate cancer PC3 cells (Malik et al 2005).  
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The two apoptosis markers Bax and Bak showed increased expression, while the cell 
proliferation markers cyclins D1, D2, and E and cdk 2, 4, and 6 expression was decreased.  In 
another animal study, ellagic acid inhibited DMH-induced activation of PI3K/Akt and influenced 
the downstream Bcl-2 family proteins (Umesalma and Sudhandiran 2011).  Administration of 
ellagic acid in rats upregulated Bax and caspases-3 which elevated cytochrome c levels and 
finally led to cell death.  
7.5 Effect of Gallic Acid on HT-29 and HCT 116 Cells 
Gallic acid (3, 4, 5-trihydroyl-benzoic acid) is present in several plants, fruits and foods 
such as cereals, legumes, tea leaves, and whole grain bread (Salucci et al., 2002, You and Park, 
2010, Djordjevic et al., 2011).  Gallic acid is readily absorbed by humans, as consumption of 
gallic acid rich food and gallic acid tablet, caused several micromoles of free gallic acid and 
glucuronidated forms of gallic acid and its main metabolite, 4-O-methyl gallic acid, in human 
blood plasma (Shahrzad et al., 2001; You and Park, 2010).  
Gallic acid induces programmed cell death in various tumor cell lines like in leukemia, 
lung, breast, colon and gastric cancer (Inoue et al., 2000; Ohno et al., 1999; Faried et al., 2007).  
Gallic acid inhibits the growth of colon cancer cell lines (Caco-2, HT-29, Colo-201), and in vivo 
studies on colon carcinogenesis (Salucci et al., 2002; Faried et al., 2007).  In Wistar rats 
administration of gallic acid restored colon specific carcinogen induced histological changes and 
xenobiotic-metabolizing enzyme systems, thus reducing the incidence of colon cancer (Giftson et 
al., 2011). 
Our data showed that gallic acid-treated cells reduced markers for all three processes — 
cell proliferation, apoptosis and inflammatory pathway — which is in agreement with previous 
studies that gallic acid is associated with induced anti-proliferation and/or apoptotic activities  in 
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various cancers (Inoue et al., 2000; Salucci et al., 2002; Faried et al., 2007; You and Park, 2010).  
Gallic acid has very low IC50, thus confirming its high potency and suggests that gallic acid could 
be a very effective chemopreventive.  
7.6 Effect of Caffeic Acid on HT-29 and HCT 116 Cells 
 Caffeic acid is one of the major representative hydroxycinnamic acids, and occurs in 
foods mainly as an ester with quinic acid (Boerjan et al., 2003).  The hydroxylation produces 
caffeic acid ester of shikimic acid, which converts to chlorogenic acid (Boerjan et al., 2003).  
Coffee contains high level of caffeic acid.  The caffeic acid content of a 200 mL cup of coffee 
has been reported to range about 35 to 175 mg (Clifford, 2000). 
 Caffeic acid has been shown to inhibit growth of several cancers such as 
hepatocarcinoma HepG2 (Chung et al., 2004) and human ovarian cancer A2780 cells (Tai et al., 
2010).  12-O-tetradecanoylphorbol-13-acetate (TPA)-induced epidermal tumors in mice were 
reduced by 28% and 35% when simultaneously administered with chlorogenic acid or caffeic 
acid, respectively (Huang et al., 1988).  
To our knowledge, studies showing the anti-proliferation and pro-apoptotic activity of 
caffeic acid on both HT-29 and HCT 116 human colon cancer cell lines are scarce and not well-
documented.  Caffeic acid had growth inhibitory effect on both human colon cancer HT-29 and 
HCT 116 cells.  However, caffeic acid showed the most anti-proliferation effect on HT-29 cells 
compared to HCT 116 cells, anti-proliferative IC50 of 0.06 mM and 0.22 mM respectively.  In 
our study, caffeic acid induced anti-proliferation and apoptotic activities in both cell lines are 
associated with downregulation of Cyclin D1 and upregulation of Bax.  
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7.7 Effect of Chlorogenic Acid on HT-29 Cells 
Chlorogenic acids are a family of esters formed between a trans-cinnamic acid such as 
caffeic acid or ferulic acid and quinic acid which has axial hydroxyls on carbon 1 and 3 and 
equatorial hydroxyls on carbon 4 and 5 (Clifford, 2000).  Intestinal microorganisms hydrolyze 
chlorogenic acid into various aromatic acid metabolites including caffeic acid and quinic acid 
(Gonthier et al., 2003).  It is widespread in plants, fruits, grains, and vegetables (Clifford, 2000; 
Verma et al., 2009).  For example, coffee is one of the beverages containing large amount of 
phenolic acids, especially chlorogenic acid, which in a single cup (200 mL) of coffee varies 
between 70 and 350 mg (Clifford, 2000).   
Chlorogenic acid shows anti-proliferative activity and induces apoptosis in several human 
cancer cell lines such as oral squamous cell carcinoma HSC-2, salivary gland tumor HSG (Jiang 
et al., 2000), and human ovarian cancer A2780 cells (Tai et al., 2010).  Chlorogenic acid exhibits 
anti-mutagenic, anti-carcinogenic, anti-oxidant activities, and ability to scavenge reactive oxygen 
species (Rice-Evans et al., 1996).  
To our knowledge, there are few if any reports showing the anti-proliferation and pro-
apoptotic activity of chlorogenic acid on both HT-29 and HCT 116 human colon cancer cell 
lines.  Chlorogenic acid was more effective in preventing HT-29 cells than that of the HCT 116 
cells.  The anti-proliferation IC50 concentrations for chlorogenic acid on HT-29 and HCT 116 
cells were 0.28 mM and 1.10 mM respectively.  In our study, the chlorogenic acid upregulated 
Bax and downregulated Cyclin D1 proteins, suggesting it induced apoptosis and inhibited cell 
proliferative activity. 
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7.8 Anti-oxidant Capacities of Phenolic Acids  
The eleven phenolic acids’ concentrations, profiles, and anti-oxidant capacities (Table  
7.5) from the bran of six wheat cultivars were determined (Verma et al., 2009) and were used in 
this study to screen their effects on prevention colon cancer cell growth.  The two anti-oxidant 
assays also show differential activity, suggesting that phenolics react differentially to the DPPH 
and ABTS radicals (Verma et al., 2009).      
The benzoic acid derivatives ellagic acid and gallic acid had very high anti-oxidant 
activity as measured by DPPH assay and also had very low IC50 values suggesting these are 
potent agents to reduce the growth of colon cancer cells (Table 7.3).  However, 2, 5-dihydroxy 
benzoic acid which showed the highest DPPH based anti-oxidant activity showed very high IC50 
for both the cell lines.  In the cinnamic acid derivatives both caffeic acid and chlorogenic acid 
show high DPPH based anti-oxidant activity and low IC50 in both cell lines, but more in HT-29 
as compared to HCT 116 (Table 7.3).  These results showed some relationship between anti-
oxidant activity and the inhibitory effect on the growth of the two cell lines.  However, this 
limited study provided no definite conclusions regarding the structure of phenols and anti-
oxidant activity and inhibition of cell growth.   
7.9 General Conclusions 
A major finding of this study is that both the cell lines HT-29 and HCT 116 can be used 
to screen the anti-carcinogenic activity of plant-based chemical compounds.  The two cell lines 
differed in their genetics and some biochemical markers associated with cancer development.  
However, detailed marker analysis clearly showed that pro-apoptosis marker was increased in 
both the cell lines in response to most of the phenolic acids studied.  Bax marker expression also 
increased in HT-29 colon cancer lines treated with bilberry (Vaccinium myrtillus) or cloudberry 
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(Rubus chamaemorous) extracts (Wu et al., 2007).  These results suggest that phenolic acid 
treatment predisposes the cells to apoptosis as one of the mechanisms to prevent colon cancer.   
 
Table 7.3.  Anti-oxidant activity of 50 µg ml
-1
 phenolic acid standards.  Anti-oxidant is 
expressed as percent discolouration of 2, 2-diphenyl-1-picrylhydrazyl (DPPH).  Negative number 
indicates increased colouration of the radical solution.  (*Data adapted from Verma et al., 2009) 
 
Phenolic acids 
Molecular 
Weight 
(g/mol) 
IC50 (mM) 
Anti-oxidant 
Value * 
HT-29 HCT 116 DPPH ABTS 
Benzoic Acid Derivatives 
Ellagic acid 302.19 1.32 0.17 49.0 0.12 
Gallic acid 170.12 0.30 0.15 60.2 1.17 
Protocatechuic acid 182.17 2.20 2.20 17.2 0.48 
Salicylic acid 138.12 2.90 2.90 -6.4 0.003 
Syringic acid 198.17 2.02 4.04 7.3 0.45 
Vanillic acid 168.15 2.38 4.76 -5.8 0.35 
2, 5-Dihydroxybenzoic 
acid 
154.12 2.60 5.19 78.9 0.48 
4-Hydroxybenzoic acid 138.12 2.90 5.79 4.1 -0.019 
Cinnamic Acid Derivatives 
Caffeic acid 180.16 0.06 0.22 26.9 0.39 
Chlorogenic acid 363.32 0.28 1.10 22.0 0.17 
p-Coumaric acid 164.16 2.44 1.22 1.5 0.47 
Ferulic acid 194.18 2.06 2.06 8.1 0.64 
Sinapic acid 224.21 1.78 3.57 17.4 0.41 
3, 4-Dimethoxycinnamic 
acid 
182.17 1.10 2.20 1.2 -0.02 
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The cell proliferation markers were negatively correlated to phenolic acid treatment, 
suggesting that phenolic acid treatment inhibited cell division.   Cell inflammatory markers were 
mostly negatively correlated with phenolic acid treatment; however, the trends were not 
consistent, thus indicating that phenolic acid treatment affected different cell inflammatory 
pathways.  Higher anti-oxidant activity to some extent influenced cell growth of both the cell 
lines.  However, the results were not conclusive to draw some definitive conclusions. 
7.10 Future Directions 
These studies have provided some very interesting observations and established a 
protocol to study the effect of phenolic acids or other plant constituents on two different colon 
cancer lines.  Definite conclusions on the molecular mechanisms underlying cell growth 
inhibition by the phenolic acids could not be elucidated from this study.   Immunohistochemical 
studies are good indicators of the presence of marker proteins, but to identify the molecular 
mechanism underlying the response, precise gene expression studies using RNA gel blot 
(Northern hybridization) and or real-time quantitative PCR will be needed to be done. To 
understand the role of wheat bran products in colon cancer prevention, studies should be carried 
out with pre-analyzed wheat bran extracts using the two colon cancer lines and methods 
developed in this project.  Different wheat varieties have different bran compositions, with 
different ant-oxidant activities.  Another important study that can be done is to investigate the 
interaction of one or more phenolic acids in prevention of growtn of colon cancer cell lines.   
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9.0 APPENDIX 
 
 
Appendix 1.  Representative photographs of histological sections of human colon carcinoma cell 
line HT-29 treated with chlorogenic acid.  The Cyclin D1 proteins in (A) Control or 0 µg/mL, 
(B) 10 µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, and (E) 400 µg/mL are nucleus staining.  Note 
brown-stained Cyclin D1 proteins (red arrows). 
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Appendix 2.  Representative photographs of histological sections of human colon carcinoma cell 
line HT-29 treated with chlorogenic acid.  The Ki67 proteins in (A) Control or 0 µg/mL, (B) 10 
µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, and (E) 400 µg/mL are nucleus staining.  Note brown-
stained Ki67 proteins (red arrows). 
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Appendix 3.  Representative photographs of histological sections of human colon carcinoma cell 
line HT-29 treated with chlorogenic acid.  The Bax proteins in (A) Control or 0 µg/mL, (B) 10 
µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, and (E) 400 µg/mL are cytoplasmic staining.  Note 
brown-stained Bax proteins (red arrows). 
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Appendix 4.  Representative photographs of histological sections of human colon carcinoma cell 
line HT-29 treated with chlorogenic acid.  The Bcl-2 proteins in (A) Control or 0 µg/mL, (B) 10 
µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, and (E) 400 µg/mL are cytoplasmic staining.  Note 
brown-stained Bcl-2 proteins. 
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Appendix 5.  Representative photographs of histological sections of human colon carcinoma cell 
line HT-29 treated with chlorogenic acid.  The beta-catenin proteins in (A) Control or 0 µg/mL, 
(B) 10 µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, and (E) 400 µg/mL are cytoplasmic staining.  
Note brown-stained beta-catenin proteins (red arrows). 
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Appendix 6.  Representative photographs of histological sections of human colon carcinoma cell 
line HT-29 treated with chlorogenic acid.  The iNOS  proteins in (A) Control or 0 µg/mL, (B) 10 
µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, and (E) 400 µg/mL are cytoplasmic staining.  Note 
brown-stained iNOS proteins (red arrows). 
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Appendix 7.  Representative photographs of histological sections of human colon carcinoma cell 
line HCT 116 treated with ellagic acid.  The Cyclin D1 proteins in (A) Control or 0 µg/mL, (B) 
10 µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, (E) 400 µg/mL, and (F) 800 µg/mL are nucleus 
staining.  Note brown-stained Cyclin D1 proteins (red arrows). 
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Appendix 8.  Representative photographs of histological sections of human colon carcinoma cell 
line HCT 116 treated with ellagic acid.  The Ki67 proteins in (A) Control or 0 µg/mL, (B) 10 
µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, (E) 400 µg/mL, and (F) 800 µg/mL are nucleus 
staining.  Note brown-stained Ki67 proteins (red arrows). 
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Appendix 9.  Representative photographs of histological sections of human colon carcinoma cell 
line HCT 116 treated with ellagic acid.  The Bax proteins in (A) Control or 0 µg/mL, (B) 10 
µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, (E) 400 µg/mL, and (F) 800 µg/mL are cytoplasmic 
staining.  Note brown-stained Bax proteins (red arrows). 
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Appendix 10.  Representative photographs of histological sections of human colon carcinoma 
cell line HCT 116 treated with ellagic acid.  The Bcl-2 proteins in (A) Control or 0 µg/mL, (B) 
10 µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, (E) 400 µg/mL, and (F) 800 µg/mL are cytoplasmic 
staining.  Note brown-stained Bcl-2 proteins. 
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Appendix 11.  Representative photographs of histological sections of human colon carcinoma 
cell line HCT 116 treated with ellagic acid.  The beta-catenin proteins in (A) Control or 0 µg/mL, 
(B) 10 µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, (E) 400 µg/mL, and (F) 800 µg/mL are 
cytoplasmic staining.  Note brown-stained beta-catenin proteins (red arrows). 
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Appendix 12.  Representative photographs of histological sections of human colon carcinoma 
cell line HCT 116 treated with ellagic acid.  The iNOS proteins in (A) Control or 0 µg/mL, (B) 
10 µg/mL, (C) 100 µg/mL, (D) 200 µg/mL, (E) 400 µg/mL, and (F) 800 µg/mL are cytoplasmic 
staining.  Note brown-stained iNOS proteins (red arrows). 
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Appendix 13.  Relative quantitation of Western Blot of cell treatments from either human colon 
cancer cell line HT-29 or HCT 116 probed with primary antibody against Bax or Cyclin D1.  The 
numbers indicate the number-fold increase or reduce of each specific immunoreactive band 
compared with its control, to which a value of 1 was assigned to be equal. ―nd‖, not detectable.  
 
 
 
Polypeptide (Cell line – Phenolic acid used) Control 
 
10 
 
 
100 
 
 
200 
 
 
400 
 
 
800 
 
(a) Bax (HCT 116 – Caffeic acid) 1.00 1.30 1.68 3.51 nd nd 
(b) Bax (HCT 116 – Ellagic acid) 1.00 1.38 2.27 2.42 2.47 nd 
(c) Bax (HCT 116 – Gallic acid) 1.00 1.05 nd nd nd nd 
(d) Cyclin D1 (HCT 116 – Caffeic acid) 1.00 0.66 0.50 0.46 nd nd 
(e) Cyclin D1 (HCT 116 – Ellagic acid) 1.00 0.98 0.77 0.49 0.34 nd 
(f) Cyclin D1 (HCT 116 – Gallic acid) 1.00 0.81 nd nd nd nd 
(g) Bax  (HT-29 – Caffeic acid) 1.00 1.30 1.66 1.78 nd nd 
(h) Bax  (HT-29 – Chlorogenic acid) 1.00 1.29 2.10 2.08 2.75 3.12 
(i) Bax  (HT-29 – Gallic acid) 1.00 1.10 nd nd nd nd 
(j) Cyclin D1  (HT-29 – Caffeic acid) 1.00 0.19 0.00 0.00 nd nd 
(k) Cyclin D1  (HT-29 – Chlorogenic acid) 1.00 0.63 0.93 0.87 1.11 0.48 
(l) Cyclin D1  (HT-29 – Gallic acid) 1.00 0.71 nd nd nd nd 
 
 
 
